{"id":15877,"date":"2021-12-14T13:04:09","date_gmt":"2021-12-14T13:04:09","guid":{"rendered":"https:\/\/incilab.az\/hematologiya-testl%c9%99r-qrupu\/"},"modified":"2023-09-14T09:06:33","modified_gmt":"2023-09-14T09:06:33","slug":"hematology-test-group","status":"publish","type":"page","link":"https:\/\/incilab.az\/en\/hematology-test-group\/","title":{"rendered":"Hematology test group"},"content":{"rendered":"

[vc_row][vc_column]

\r\n \r\n <\/div>\r\n
<\/div>
\r\n

ABO QRUPLARI (QAN QRUPLARI V\u018f RH T\u018fY\u0130N\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0ABO qruplar\u0131<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>X\u0259s\u00adt\u0259\u00adnin ad\u0131 m\u00fctl\u0259q s\u0131naq \u015f\u00fc\u015f\u0259sinin \u00fcz\u0259\u00adrind\u0259 olmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>S\u0131naq \u015f\u00fc\u015f\u0259sind\u0259 aglu\u00adtinasiya<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Qan qruplar\u0131 v\u0259 Rh tip\u00adl\u0259n\u00addirilm\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

AC QLOBUL\u0130N (FAKTOR V)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>AC globulin; Labil faktor; Plazma akselerator globulin; Pro\u00adakselerin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan qan\/antikoaqulyant nis\u00adb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fc\u00admun\u0259l\u0259r<\/p>\n

Referens:<\/strong>\u00a0Normal aktivliyin\u00a0 50-150 %-i<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>V faktorun\u00a0 irsi \u00e7at\u0131\u00ad\u015f\u00admaz\u00adl\u0131\u011f\u0131 olan x\u0259st\u0259l\u0259rd\u0259 (parahe\u00admofiliya) anormal qanaxmalar m\u00fc\u015fahid\u0259 olu\u00adnur v\u0259 laxtalanma zaman\u0131, PT v\u0259 APTT testl\u0259rind\u0259 uzanmalar m\u00fc\u0259y\u00ady\u0259n edilir. Hamil\u0259lik zaman\u0131 bir s\u0131ra laxtalanma faktorlar\u0131 kimi V faktor\u00adda da az miqdarda art\u0131m ba\u015f ver\u0259 bil\u0259r. K\u0259skin qaraciy\u0259r \u00e7at\u0131\u015fmazl\u0131\u00ad\u011f\u0131nda sintezin z\u0259ifl\u0259m\u0259si, DDL za\u00adman\u0131 is\u0259 s\u0259rf olunman\u0131n artmas\u0131 il\u0259 \u0259laq\u0259dar olaraq V faktorun miqdar\u0131 azal\u0131r. V faktorun t\u0259yini qaraciy\u0259r x\u0259st\u0259liyi v\u0259 K vitamini \u00e7at\u0131\u015fmaz\u00adl\u0131\u011f\u0131n\u0131n differensiasiyas\u0131nda istifad\u0259 olunur. Parenximal qaraciy\u0259r x\u0259st\u0259\u00adlik\u00adl\u0259rind\u0259 V faktor v\u0259 K vita\u00admi\u00adnin\u00add\u0259n as\u0131l\u0131 sintez olunan laxtalanma faktorlar\u0131 (II, VII, IX v\u0259 X faktorlar) azald\u0131\u011f\u0131 halda, K vitamini \u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u011f\u0131nda V faktor normal, dig\u0259r fak\u00adtorlar\u0131n miqdar\u0131 is\u0259 a\u015fa\u011f\u0131 olur. Bu m\u0259q\u00ads\u0259dl\u0259 V v\u0259 VII faktorlar\u0131n aktiv\u00adliyi t\u0259yin oluna bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

AKT\u0130V PARS\u0130AL TROMBOPLAST\u0130N ZAMANI<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>aPTT, Parsial trombo\u00adplas\u00adtin zaman\u0131, PTT<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:\u00a0<\/strong>mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcl<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>n\u00fc\u00admu\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admo\u00adliz\u0259 u\u011framadan tez ayr\u0131lmal\u0131 v\u0259 so\u00adyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir.\u00a0X\u0259st\u0259nin haz\u0131rlanmas\u0131:\u00a0<\/strong>X\u0259st\u0259 he\u00adparin q\u0259bul edirs\u0259 n\u00f6vb\u0259ti dozadan 1 saat \u0259vv\u0259l n\u00fcmun\u0259 al\u0131nmal\u0131d\u0131r. He\u00adparin vurulan qoldan qan al\u0131nma\u00admal\u0131d\u0131r.<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>Lax\u00adtalanm\u0131\u015f, hemolizli, heparinli n\u00fcmu\u00adn\u0259l\u0259r, uy\u011fun olmayan qan\/anti-koauqulyant nisb\u0259ti<\/p>\n

Referens:\u00a0<\/strong>25-36 san<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Daxili\u00a0(<\/strong>intrensek) laxta\u00adlanma sisteminin qiym\u0259tl\u0259ndirilm\u0259si, heparin m\u00fcalic\u0259sinin n\u0259zar\u0259td\u0259 sax\u00adlan\u0131lmas\u0131, A v\u0259 B hemofiliyan\u0131n skri\u00adninqi, II, V, VIII, IX, X, XI v\u0259 XII faktorlar\u0131n kongenital \u00e7at\u0131\u015fmazl\u0131q\u00adla\u00adr\u0131n\u0131n skrininqi, DIC, disfibrino\u00adge\u00adne\u00admiya, qaraciy\u0259r \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, d\u00f6vr ed\u0259n anti-koaqulyantlar v\u0259 K vita\u00admini \u00e7at\u0131\u015fmazl\u0131\u011f\u0131n\u0131n qiym\u0259tl\u0259ndiril\u00adm\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

AKT\u0130V PROTE\u0130N C RES\u0130ZTENTL\u0130Y\u0130<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>APC rezistentliyi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:\u00a0<\/strong>mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>300 ml<\/p>\n

N\u00fcnum\u0259 alma:\u00a0<\/strong>n\u00fcmun\u0259 al\u0131nd\u0131qdan s\u0131nra plazma hemoliz\u0259 u\u011framadan d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>lax\u00adtalanm\u0131\u015f, hemoliz\u0259 u\u011fram\u0131\u015f, hepa\u00adrinli n\u00fcmun\u0259l\u0259r, qan\/antikoaqulyant nisb\u0259ti d\u00fcz olmayan n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:\u00a0<\/strong>APC rezistentliyi normalla\u015fd\u0131rma \u0259msal\u0131: 0.69-1.56. APC rezistentliyi normalla\u015fd\u0131rma nisb\u0259ti\/FV Leiden: 0.86-1.10<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u018fsas\u0259n faktor V Leiden mutasiyas\u0131 il\u0259 \u0259laq\u0259dar olaraq inki\u015faf ed\u0259n APC rezistentliyinin ara\u015fd\u0131r\u0131l\u00admas\u0131nda skrininq test kimi istifa\u00add\u0259\u00ad olunur. Test iki formada apar\u0131l\u0131r v\u0259 n\u0259tic\u0259 verilir. Birinci formada (APC rezistentliyi normalla\u015fd\u0131rma \u0259msal\u0131), x\u00fcsusil\u0259 kumadin istifad\u0259 ed\u0259n x\u0259s\u00adt\u0259l\u0259rd\u0259 protein C v\u0259 S miqdar\u0131 azal\u00add\u0131\u011f\u0131 \u00fc\u00e7\u00fcn a\u015fa\u011f\u0131 n\u0259tic\u0259l\u0259r \u0259ld\u0259 oluna bil\u0259r. Referensdan ki\u00e7ik n\u0259tic\u0259l\u0259r APC rezistentliyini v\u0259 ya protein C v\u0259 S miqdar\u0131n\u0131n az ola bil\u0259c\u0259yini g\u00f6s\u00adt\u0259rir. \u0130kincisind\u0259 is\u0259 (APC re\u00adzistentliyi normalla\u015fd\u0131rma nisb\u0259ti\/FV Leiden) yaln\u0131z APC rezistentliyi qiy\u00adm\u0259tl\u0259ndirilir. Oral antikoaqul\u00adyant\u00adla\u00adr\u0131n istifad\u0259si bu test\u0259 t\u0259sir g\u00f6st\u0259rmir v\u0259 referensd\u0259n ki\u00e7ik n\u0259tic\u0259l\u0259r APC rezistentliyini g\u00f6st\u0259rir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ANT\u0130-FAKTOR XA<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admu\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admo\u00adliz\u0259 u\u011framadan d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan qan\/antikoaqulyant nisb\u0259ti, laxtal\u0131, heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:<\/strong>\u00a0 >12 ya\u015f \u00a0\u00a0\u00a0\u00a00.4-1.1 U\/mL<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ANT\u0130HEMOF\u0130L\u0130YA FAKTORU (FAKTOR VIII)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Antihemofiliya faktoru<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan tez ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Risk qiy\u00adm\u0259t\u00adl\u0259ndirilm\u0259si apar\u0131ld\u0131qdan sonra heparin m\u00fcalic\u0259si m\u00fcayin\u0259d\u0259n 2 g\u00fcn \u0259vv\u0259l k\u0259silm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Kaoqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan qan\/anti\u00adkoa\u00adqul\u00adyant\u00adnisb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:\u00a0<\/strong>Normal aktivliyin 50-150 %-i<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u0130rsi VIII faktorun \u00e7at\u0131\u015f\u00admazl\u0131\u011f\u0131 (hemofiliya A) X-\u0259 ba\u011fl\u0131 ke\u00e7\u0259n v\u0259 qanaxmaya meyillilikl\u0259 xa\u00adrakteriz\u0259 olunan x\u0259st\u0259likdir. Klinik olaraq VIII faktorun \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, x\u0259s\u00adt\u0259nin plazmas\u0131nda VIII faktorun s\u0259viyy\u0259sind\u0259n as\u0131l\u0131 olaraq, \u015fidd\u0259tli (<1%), orta d\u0259r\u0259c\u0259 (1-5%) v\u0259 y\u00fcng\u00fcl (>5%) d\u0259r\u0259c\u0259l\u0259r\u0259 ayr\u0131l\u0131r. H\u0259min \u015f\u0259xs\u00ad\u00adl\u0259rd\u0259 aPTT uzand\u0131\u011f\u0131 halda, PT v\u0259 TT normal olur. H\u0259m\u00e7inin VIII faktor k\u0259skin faza reaktant\u0131 olub, esterogenl\u0259rin istifad\u0259si, qaraciy\u0259r x\u0259st\u0259liyi, \u015f\u0259k\u0259rli diabet, stress hallar\u0131 v\u0259 ya idman h\u0259r\u0259k\u0259tl\u0259rind\u0259n sonra y\u00fcks\u0259l\u0259 bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ANT\u0130HEMOF\u0130L\u0130YA FAKTORU BC (FAKTOR IX)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Anti-hemofiliya faktoru B; Christmas faktoru; Autoprotrombin II<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admu\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admo\u00adliz\u0259 u\u011framadan tez ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Risk qiy\u00adm\u0259t\u00adl\u0259ndirm\u0259 apar\u0131ld\u0131qdan sonra ku\u00admadin cinsli antikoaqulyant istifad\u0259 ed\u0259n x\u0259s\u00adt\u0259l\u0259rd\u0259 2 h\u0259ft\u0259, heparin m\u00fca\u00adlic\u0259sind\u0259 is\u0259 2 g\u00fcn \u0259vv\u0259l m\u00fcalic\u0259 k\u0259silm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>Kaoqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan qan\/antikoaqulyant nis\u00adb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fc\u00admun\u0259l\u0259r<\/p>\n

Referens:\u00a0<\/strong>Normal aktivliyin 50-150%-i<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u0130rsi IX faktorun \u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u011f\u0131 (hemofiliya B), \u201cX\u201d il\u0259 \u0259laq\u0259li ke\u00e7\u0259n, qanaxma diatezi v\u0259 plazmada IX faktor aktivliyinin az olmas\u0131 il\u0259 xarakteriz\u0259 olunan x\u0259st\u0259likdir. \u018fsa\u00ads\u0259n ki\u015fil\u0259rd\u0259 rast g\u0259linir, qad\u0131nlar is\u0259 da\u015f\u0131y\u0131c\u0131d\u0131r. 1\/25000 tezliyind\u0259\u00a0 rast g\u0259\u00adlinir. Bu x\u0259st\u0259l\u0259rd\u0259 APTT uzan\u0131r, PT normal olur.\u00a0 Qazan\u0131lm\u0131\u015f IX fak\u00adtor \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 is\u0259 oral anti\u00adkoa\u00adqul\u00adyantlar\u0131n istifad\u0259si, a\u011f\u0131r qaraciy\u0259r x\u0259s\u00adt\u0259liyi v\u0259 K vitamini \u00e7at\u0131\u015fmaz\u00adl\u0131\u011f\u0131nda m\u00fc\u015fahid\u0259 oluna bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ANT\u0130TROMB\u0130N III<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>AT III; Heparin kofaktor \u00e7al\u0131\u015fmas\u0131<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>200 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admu\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admo\u00adliz\u0259 u\u011framadan d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>Uy\u00ad\u011fun olmayan qan\/antikoaqulyant nis\u00adb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fc\u00admun\u0259l\u0259r<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
< 3 ay<\/td>\n35-125%<\/td>\n<\/tr>\n
>3ay<\/td>\n70-125%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>AT III \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 hi\u00adper\u00adkoaquliyasiyaya s\u0259b\u0259b olan faktor\u00adlar\u00addan biridir. AT III azl\u0131\u011f\u0131 genetik (auto\u00adsom dominant) v\u0259 ya qaza\u00adn\u0131lm\u0131\u015f s\u0259\u00adb\u0259bl\u0259rl\u0259 \u0259laq\u0259dar ola bil\u0259r. A\u011f\u0131r sirroz, DIC, a\u011fciy\u0259r emboliyas\u0131 v\u0259 c\u0259rrahi \u0259m\u0259liyatlar qazan\u0131lm\u0131\u015f s\u0259b\u0259bl\u0259rd\u0259ndir. F\u0259rdi v\u0259 ya irsi trombemboliya x\u0259s\u00adt\u0259\u00adliyi olanlarda v\u0259 yet\u0259rsiz heparin m\u00fca\u00adli\u00adc\u0259si zaman\u0131\u00a0 AT III s\u0259viyy\u0259si t\u0259yin olunmal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

APC REZ\u0130STENTL\u0130Y\u0130 (AKT\u0130V PROTE\u0130N C RES\u0130ZTENTL\u0130Y\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>APC rezistentliyi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:\u00a0<\/strong>mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>300 ml<\/p>\n

N\u00fcnum\u0259 alma:\u00a0<\/strong>n\u00fcmun\u0259 al\u0131nd\u0131qdan s\u0131nra plazma hemoliz\u0259 u\u011framadan d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>lax\u00adtalanm\u0131\u015f, hemoliz\u0259 u\u011fram\u0131\u015f, hepa\u00adrinli n\u00fcmun\u0259l\u0259r, qan\/antikoaqulyant nisb\u0259ti d\u00fcz olmayan n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:\u00a0<\/strong>APC rezistentliyi normalla\u015fd\u0131rma \u0259msal\u0131: 0.69-1.56. APC rezistentliyi normalla\u015fd\u0131rma nisb\u0259ti\/FV Leiden: 0.86-1.10<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u018fsas\u0259n faktor V Leiden mutasiyas\u0131 il\u0259 \u0259laq\u0259dar olaraq inki\u015faf ed\u0259n APC rezistentliyinin ara\u015fd\u0131r\u0131l\u00admas\u0131nda skrininq test kimi istifa\u00add\u0259\u00ad olunur. Test iki formada apar\u0131l\u0131r v\u0259 n\u0259tic\u0259 verilir. Birinci formada (APC rezistentliyi normalla\u015fd\u0131rma \u0259msal\u0131), x\u00fcsusil\u0259 kumadin istifad\u0259 ed\u0259n x\u0259s\u00adt\u0259l\u0259rd\u0259 protein C v\u0259 S miqdar\u0131 azal\u00add\u0131\u011f\u0131 \u00fc\u00e7\u00fcn a\u015fa\u011f\u0131 n\u0259tic\u0259l\u0259r \u0259ld\u0259 oluna bil\u0259r. Referensdan ki\u00e7ik n\u0259tic\u0259l\u0259r APC rezistentliyini v\u0259 ya protein C v\u0259 S miqdar\u0131n\u0131n az ola bil\u0259c\u0259yini g\u00f6s\u00adt\u0259rir. \u0130kincisind\u0259 is\u0259 (APC re\u00adzistentliyi normalla\u015fd\u0131rma nisb\u0259ti\/FV Leiden) yaln\u0131z APC rezistentliyi qiy\u00adm\u0259tl\u0259ndirilir. Oral antikoaqul\u00adyant\u00adla\u00adr\u0131n istifad\u0259si bu test\u0259 t\u0259sir g\u00f6st\u0259rmir v\u0259 referensd\u0259n ki\u00e7ik n\u0259tic\u0259l\u0259r APC rezistentliyini g\u00f6st\u0259rir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

APTT (AKT\u0130V PARS\u0130AL TROMBOPLAST\u0130N ZAMANI)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>aPTT, Parsial trombo\u00adplas\u00adtin zaman\u0131, PTT<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:\u00a0<\/strong>mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcl<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>n\u00fc\u00admu\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admo\u00adliz\u0259 u\u011framadan tez ayr\u0131lmal\u0131 v\u0259 so\u00adyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir.\u00a0X\u0259st\u0259nin haz\u0131rlanmas\u0131:\u00a0<\/strong>X\u0259st\u0259 he\u00adparin q\u0259bul edirs\u0259 n\u00f6vb\u0259ti dozadan 1 saat \u0259vv\u0259l n\u00fcmun\u0259 al\u0131nmal\u0131d\u0131r. He\u00adparin vurulan qoldan qan al\u0131nma\u00admal\u0131d\u0131r.<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>Lax\u00adtalanm\u0131\u015f, hemolizli, heparinli n\u00fcmu\u00adn\u0259l\u0259r, uy\u011fun olmayan qan\/anti-koauqulyant nisb\u0259ti<\/p>\n

Referens:\u00a0<\/strong>25-36 san<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Daxili\u00a0(<\/strong>intrensek) laxta\u00adlanma sisteminin qiym\u0259tl\u0259ndirilm\u0259si, heparin m\u00fcalic\u0259sinin n\u0259zar\u0259td\u0259 sax\u00adlan\u0131lmas\u0131, A v\u0259 B hemofiliyan\u0131n skri\u00adninqi, II, V, VIII, IX, X, XI v\u0259 XII faktorlar\u0131n kongenital \u00e7at\u0131\u015fmazl\u0131q\u00adla\u00adr\u0131n\u0131n skrininqi, DIC, disfibrino\u00adge\u00adne\u00admiya, qaraciy\u0259r \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, d\u00f6vr ed\u0259n anti-koaqulyantlar v\u0259 K vita\u00admini \u00e7at\u0131\u015fmazl\u0131\u011f\u0131n\u0131n qiym\u0259tl\u0259ndiril\u00adm\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

AT III (ANT\u0130TROMB\u0130N III)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>AT III; Heparin kofaktor \u00e7al\u0131\u015fmas\u0131<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>200 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admu\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admo\u00adliz\u0259 u\u011framadan d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>Uy\u00ad\u011fun olmayan qan\/antikoaqulyant nis\u00adb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fc\u00admun\u0259l\u0259r<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
< 3 ay<\/td>\n35-125%<\/td>\n<\/tr>\n
>3ay<\/td>\n70-125%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>AT III \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 hi\u00adper\u00adkoaquliyasiyaya s\u0259b\u0259b olan faktor\u00adlar\u00addan biridir. AT III azl\u0131\u011f\u0131 genetik (auto\u00adsom dominant) v\u0259 ya qaza\u00adn\u0131lm\u0131\u015f s\u0259\u00adb\u0259bl\u0259rl\u0259 \u0259laq\u0259dar ola bil\u0259r. A\u011f\u0131r sirroz, DIC, a\u011fciy\u0259r emboliyas\u0131 v\u0259 c\u0259rrahi \u0259m\u0259liyatlar qazan\u0131lm\u0131\u015f s\u0259b\u0259bl\u0259rd\u0259ndir. F\u0259rdi v\u0259 ya irsi trombemboliya x\u0259s\u00adt\u0259\u00adliyi olanlarda v\u0259 yet\u0259rsiz heparin m\u00fca\u00adli\u00adc\u0259si zaman\u0131\u00a0 AT III s\u0259viyy\u0259si t\u0259yin olunmal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

AUTOPROTOMB\u0130N C (FAKTOR X)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Stuart faktoru; auto\u00adpro\u00adtrombin C; autoprotrombin III<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admu\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan tez ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Risk qiy\u00adm\u0259tl\u0259ndirilm\u0259 apar\u0131ld\u0131qdan sonra ku\u00admadin cinsli antikoaqulyant istifad\u0259 ed\u0259n x\u0259st\u0259l\u0259rd\u0259 2 h\u0259ft\u0259, heparin m\u00fca\u00adli\u00adc\u0259\u00adsind\u0259 is\u0259 2 g\u00fcn \u0259vv\u0259l m\u00fca\u00adlic\u0259 k\u0259silm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan qan\/antikoaqul\u00adyant\u00adnisb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:\u00a0<\/strong>Normal aktivliyin 50-150%-i<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u0130rsi X faktor \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 olan x\u0259st\u0259l\u0259rd\u0259 PT v\u0259 APTT uzanm\u0131\u015f, TT is\u0259 normald\u0131r. X faktor \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 autosom resessiv ke\u00e7ir. Qazan\u0131lm\u0131\u015f X faktor \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 is\u0259 birincili amiloidoz il\u0259 \u0259laq\u0259dard\u0131r. Bundan ba\u015fqa, oral antikoaqul\u00adyant\u00adlar\u0131n istifad\u0259si v\u0259 K vitamini \u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u011f\u0131nda da X faktorun miqdar\u0131 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

AUTOPROTOMB\u0130N I (FAKTOR VII)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Autoprotrombin I; Pro\u00adkon\u00advertin; Stabil faktor\u00a0<\/strong><\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan tez ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:\u00a0<\/strong>Risk qiym\u0259t\u00adl\u0259ndirilm\u0259si apar\u0131ld\u0131qdan son\u00adra ku\u00adma\u00addin cinsli antikoaqulyant istifad\u0259 ed\u0259n x\u0259s\u00adt\u0259l\u0259rd\u0259 2 h\u0259ft\u0259, heparin m\u00fcali\u00adc\u0259\u00adsin\u00add\u0259 is\u0259 2 g\u00fcn \u0259vv\u0259l m\u00fcalic\u0259 k\u0259silm\u0259\u00adlidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Kaoqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>Uy\u00ad\u011fun olmayan qan\/antikoaqulyant nis\u00adb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:\u00a0<\/strong>Normal aktivliyin 50-150%-i<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>VII faktorun \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, nadir rast g\u0259lin\u0259n, autosom resessiv ke\u00e7\u0259n irsi x\u0259st\u0259likdir. X\u0259st\u0259lik olan \u015f\u0259xsl\u0259rd\u0259 PT uzan\u0131r, APTT is\u0259 nor\u00admal olur. Klinik qanaxman\u0131n \u015fidd\u0259ti VII faktorun aktivlik s\u0259viyy\u0259si il\u0259 \u0259la\u00adq\u0259\u00addard\u0131r. Qaraciy\u0259r x\u0259st\u0259liyi v\u0259 K vita\u00admini \u00e7at\u0131\u015fmazn\u0131\u011f\u0131n\u0131n differen\u00adsiasi\u00adya\u00ads\u0131ndada istifad\u0259 olunur. Pa\u00adrenximal qaraciy\u0259r x\u0259st\u0259likl\u0259rind\u0259 V faktor v\u0259 K vitaminind\u0259n as\u0131l\u0131 sintez olunan lax\u00adta\u00adlanma faktorlar\u0131 (II, VII, IX v\u0259 X) azal\u00add\u0131\u011f\u0131 halda, K vitamini \u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u011f\u0131nda V faktor normal, di\u00adg\u0259r faktor s\u0259viyy\u0259l\u0259ri is\u0259 a\u015fa\u011f\u0131 olur. Bu m\u0259qs\u0259dl\u0259 V v\u0259 VII faktorlar\u0131n ak\u00adtivliyi t\u0259yin oluna bil\u0259r. Oral kon\u00adtraseptiv istifad\u0259 ed\u0259n qad\u0131nlar\u0131n plazmalar\u0131 4o<\/sup>C-d\u0259 sax\u00adlan\u0131ld\u0131qda VII faktorun aktivliyind\u0259 10 d\u0259f\u0259y\u0259 q\u0259\u00add\u0259r art\u0131m m\u00fc\u015fahid\u0259 oluna bil\u0259r. H\u0259m\u00ad\u00e7inin VII faktorun aktiv\u00adliyinin artmas\u0131 miokard infarkt\u0131 riskini d\u0259 art\u0131r\u0131r. Oral antikoaqulyantlar\u0131n is\u00adtifad\u0259si, a\u011f\u0131r qaraciy\u0259r x\u0259st\u0259liyi v\u0259 K vitamini \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 hallar\u0131nda is\u0259 VII faktorun s\u0259viyy\u0259sind\u0259 azalmalar m\u00fc\u00ad\u015fahid\u0259 oluna bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

AUTOPROTOMB\u0130N II (FAKTOR IX)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Anti-hemofiliya faktoru B; Christmas faktoru; Autoprotrombin II<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admu\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admo\u00adliz\u0259 u\u011framadan tez ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Risk qiy\u00adm\u0259t\u00adl\u0259ndirm\u0259 apar\u0131ld\u0131qdan sonra ku\u00admadin cinsli antikoaqulyant istifad\u0259 ed\u0259n x\u0259s\u00adt\u0259l\u0259rd\u0259 2 h\u0259ft\u0259, heparin m\u00fca\u00adlic\u0259sind\u0259 is\u0259 2 g\u00fcn \u0259vv\u0259l m\u00fcalic\u0259 k\u0259silm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>Kaoqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan qan\/antikoaqulyant nis\u00adb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fc\u00admun\u0259l\u0259r<\/p>\n

Referens:\u00a0<\/strong>Normal aktivliyin 50-150%-i<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u0130rsi IX faktorun \u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u011f\u0131 (hemofiliya B), \u201cX\u201d il\u0259 \u0259laq\u0259li ke\u00e7\u0259n, qanaxma diatezi v\u0259 plazmada IX faktor aktivliyinin az olmas\u0131 il\u0259 xarakteriz\u0259 olunan x\u0259st\u0259likdir. \u018fsa\u00ads\u0259n ki\u015fil\u0259rd\u0259 rast g\u0259linir, qad\u0131nlar is\u0259 da\u015f\u0131y\u0131c\u0131d\u0131r. 1\/25000 tezliyind\u0259\u00a0 rast g\u0259\u00adlinir. Bu x\u0259st\u0259l\u0259rd\u0259 APTT uzan\u0131r, PT normal olur.\u00a0 Qazan\u0131lm\u0131\u015f IX fak\u00adtor \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 is\u0259 oral anti\u00adkoa\u00adqul\u00adyantlar\u0131n istifad\u0259si, a\u011f\u0131r qaraciy\u0259r x\u0259s\u00adt\u0259liyi v\u0259 K vitamini \u00e7at\u0131\u015fmaz\u00adl\u0131\u011f\u0131nda m\u00fc\u015fahid\u0259 oluna bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

AUTOPROTOMB\u0130N III (FAKTOR X)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Stuart faktoru; auto\u00adpro\u00adtrombin C; autoprotrombin III<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admu\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan tez ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Risk qiy\u00adm\u0259tl\u0259ndirilm\u0259 apar\u0131ld\u0131qdan sonra ku\u00admadin cinsli antikoaqulyant istifad\u0259 ed\u0259n x\u0259st\u0259l\u0259rd\u0259 2 h\u0259ft\u0259, heparin m\u00fca\u00adli\u00adc\u0259\u00adsind\u0259 is\u0259 2 g\u00fcn \u0259vv\u0259l m\u00fca\u00adlic\u0259 k\u0259silm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan qan\/antikoaqul\u00adyant\u00adnisb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:\u00a0<\/strong>Normal aktivliyin 50-150%-i<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u0130rsi X faktor \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 olan x\u0259st\u0259l\u0259rd\u0259 PT v\u0259 APTT uzanm\u0131\u015f, TT is\u0259 normald\u0131r. X faktor \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 autosom resessiv ke\u00e7ir. Qazan\u0131lm\u0131\u015f X faktor \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 is\u0259 birincili amiloidoz il\u0259 \u0259laq\u0259dard\u0131r. Bundan ba\u015fqa, oral antikoaqul\u00adyant\u00adlar\u0131n istifad\u0259si v\u0259 K vitamini \u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u011f\u0131nda da X faktorun miqdar\u0131 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

A\u011e QAN H\u00dcCEYR\u018f SAYI (LEYKOS\u0130T)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0A\u011f qan h\u00fcceyr\u0259l\u0259rinin say\u0131; WBC<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>1mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0H\u00fcceyr\u0259 say\u0131m\u0131<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n
Yenido\u011fulmu\u015f<\/td>\n9.0-30.0 K\/mm3<\/sup><\/td>\n<\/tr>\n
<1 ay<\/td>\n9.4-34.0 K\/mm3<\/sup><\/td>\n<\/tr>\n
2-12 ay<\/td>\n5.0-19.5 K\/mm3<\/sup><\/td>\n<\/tr>\n
1-3 ya\u015f<\/td>\n6.0-17.5 K\/mm3<\/sup><\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n5.5-15.5 K\/mm3<\/sup><\/td>\n<\/tr>\n
6-15 ya\u015f<\/td>\n4.5-13.5 K\/mm3<\/sup><\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n4.5-11.0 K\/mm3<\/sup><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Qandak\u0131 a\u011f qan h\u00fcceyr\u0259\u00adl\u0259rinin say\u0131n\u0131n qiym\u0259tl\u0259n\u00addiril\u00adm\u0259\u00adsin\u00add\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

CBC (TAM QAN SAYILMASI)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Complete blood count; CBC; Hemoqram, qanin \u00fcmumi analizi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Cell counter (h\u00fcceyr\u0259 say\u0131lmas\u0131)<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0N\u00fc\u00admun\u0259nin laxtal\u0131 olmas\u0131<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Hematoloji x\u0259st\u0259likl\u0259r, k\u0259s\u00adkin v\u0259 xroniki infeksiyalar, \u0259m\u0259\u00adliy\u00adyatdan \u0259vv\u0259l v\u0259 s. hallarda istifad\u0259 olunur. X\u0259st\u0259nin \u00fcmumi sa\u011flaml\u0131q v\u0259ziyy\u0259ti haqq\u0131nda m\u0259lumat verir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

CHR\u0130STMAS FAKTORU (FAKTOR IX)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Anti-hemofiliya faktoru B; Christmas faktoru; Autoprotrombin II<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admu\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admo\u00adliz\u0259 u\u011framadan tez ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Risk qiy\u00adm\u0259t\u00adl\u0259ndirm\u0259 apar\u0131ld\u0131qdan sonra ku\u00admadin cinsli antikoaqulyant istifad\u0259 ed\u0259n x\u0259s\u00adt\u0259l\u0259rd\u0259 2 h\u0259ft\u0259, heparin m\u00fca\u00adlic\u0259sind\u0259 is\u0259 2 g\u00fcn \u0259vv\u0259l m\u00fcalic\u0259 k\u0259silm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>Kaoqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan qan\/antikoaqulyant nis\u00adb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fc\u00admun\u0259l\u0259r<\/p>\n

Referens:\u00a0<\/strong>Normal aktivliyin 50-150%-i<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u0130rsi IX faktorun \u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u011f\u0131 (hemofiliya B), \u201cX\u201d il\u0259 \u0259laq\u0259li ke\u00e7\u0259n, qanaxma diatezi v\u0259 plazmada IX faktor aktivliyinin az olmas\u0131 il\u0259 xarakteriz\u0259 olunan x\u0259st\u0259likdir. \u018fsa\u00ads\u0259n ki\u015fil\u0259rd\u0259 rast g\u0259linir, qad\u0131nlar is\u0259 da\u015f\u0131y\u0131c\u0131d\u0131r. 1\/25000 tezliyind\u0259\u00a0 rast g\u0259\u00adlinir. Bu x\u0259st\u0259l\u0259rd\u0259 APTT uzan\u0131r, PT normal olur.\u00a0 Qazan\u0131lm\u0131\u015f IX fak\u00adtor \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 is\u0259 oral anti\u00adkoa\u00adqul\u00adyantlar\u0131n istifad\u0259si, a\u011f\u0131r qaraciy\u0259r x\u0259s\u00adt\u0259liyi v\u0259 K vitamini \u00e7at\u0131\u015fmaz\u00adl\u0131\u011f\u0131nda m\u00fc\u015fahid\u0259 oluna bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

D-D\u0130MER<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Fibrinin par\u00e7alanma m\u0259h\u00adsullar\u0131<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250\u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0N\u00fc\u00admu\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admo\u00adliz\u0259 u\u011framadan tez ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u011fun olmayan s\u0131naq \u015f\u00fc\u015f\u0259si v\u0259 qan\/antikoagulyant nisb\u0259ti, laxtal\u0131, hemolizli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:<\/strong>\u00a0<10-150 \u03bcg\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0D-Dimer s\u0259viyy\u0259sinin normadan y\u00fcks\u0259k olmas\u0131 laxtalanma, bel\u0259likl\u0259 d\u0259rin vena trombozu, a\u011f\u00adci\u00ady\u0259r emboliyas\u0131 v\u0259 ya DDL (disse\u00admi\u00adn\u0259 olunmu\u015f damardaxili laxtalanma) (disseminated intravascular coagu\u00adla\u00adtion, DIC) ehtimal\u0131n\u0131 art\u0131r\u0131r. Bundan ba\u015fqa, yumurtal\u0131q karsinomalar\u0131 v\u0259 b\u00f6yr\u0259k x\u0259st\u0259lik\u0259rind\u0259 fibrinin par\u00e7a\u00adlanmas\u0131n\u0131n t\u0259yinind\u0259, d\u0259rin vena trom\u00adbozu v\u0259 ya k\u0259skin miokard in\u00adfakt\u0131 zaman\u0131 apar\u0131lan m\u00fcalic\u0259nin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

DOLAYI COOMBS<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>500\u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Aqql\u00fctinasiya<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz, lipemiya, sar\u0131l\u0131q v\u0259 konta\u00adminasiya<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Rh(-) hamil\u0259l\u0259rd\u0259 yenido\u00ad\u011fulan\u0131n hemolitik x\u0259st\u0259lik (eritro\u00adblastozis fetalis) riskinin t\u0259yinind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

DRVVT TEST\u0130 (LUPUS ANT\u0130KOAQULYANT SKR\u0130N\u0130NQ)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0PTT-LA; LA-DVV; dRVVT testi; Dilite Russell viper venom time<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259ril\u00adm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan qan \/ antikoaqulyant miqdar\u0131, laxtal\u0131, hemolizli heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:<\/strong>\u00a0Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Lupus anticisiml\u0259ri, SLE, trombotik hallar, t\u0259krarlanan d\u00f6l it\u00adkil\u0259ri, trombositopeniya v\u0259 m\u00fcxt\u0259lif nevroloji poz\u011funluqlarla \u0259laq\u0259lidir. Dig\u0259r autoimmun poz\u011funluqlar, b\u0259d\u00adxass\u0259li t\u00f6r\u0259m\u0259l\u0259r, infeksiyalar v\u0259 b\u0259\u00adzi d\u0259rmanlar\u0131n istifad\u0259sind\u0259 d\u0259 (m\u0259s. fenotiazinl\u0259r v\u0259 \u00fcr\u0259k antiaritmik preparatlar\u0131) lupus antikoaqulyantlar\u0131 tap\u0131la bil\u0259r. Bu x\u0259st\u0259l\u0259rd\u0259 aPTT kimi fosfolipid as\u0131l\u0131 in vitro laxtalanma testl\u0259rind\u0259 uzanma ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

D\u00dcZ (B\u0130RBA\u015eA) COOMBS<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a02 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Aqql\u00fctinasiya<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>\u0130nvivo sensibilizasiyaya u\u011fram\u0131\u015f eritrositl\u0259rin a\u015fkar olun\u00adma\u00ads\u0131nda istifad\u0259 edilir. Eritroblastozis fetalis, autoimmun hemolitik ane\u00admi\u00adyalar v\u0259 uy\u011fun olmayan qan trans\u00adfu\u00adziyalar\u0131 il\u0259 \u0259laq\u0259dar \u0259m\u0259l\u0259 g\u0259l\u0259n transuzion reaksiyalar zaman\u0131 pozi\u00adtiv n\u0259tic\u0259l\u0259r m\u00fc\u015fahid\u0259 olunur. H\u0259m\u00ad\u00e7i\u00adnin d\u0259rmanla \u0259laq\u0259li hemolitik ane\u00admiyalar\u0131n t\u0259yinind\u0259 d\u0259 istifad\u0259 olu\u00adnur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

EOZ\u0130NOF\u0130L SAYI<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0H\u00fcceyr\u0259 say\u0131lmas\u0131 + mikroskopik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>N\u00fc\u00admun\u0259nin laxtalanm\u0131\u015f v\u0259 ya hemoliz\u0259 u\u011fram\u0131\u015f olmas\u0131<\/p>\n

Referens:\u00a0<\/strong>40-400 eozinofil\/mm3<\/sup><\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Alergik x\u0259st\u0259likl\u0259r, para\u00adzit infeksiyalar\u0131, kollagen vaskulyar toxuma x\u0259st\u0259likl\u0259ri, b\u0259zi hema\u00adto\u00adpoetik sistem\u00a0 x\u0259st\u0259likl\u0259ri (pernisioz anemiya, KLL, polisitemiya), post\u00adsple\u00adnektomiya, Addison x\u0259st\u0259liyi, hi\u00adpo\u00adpituiterizm, eozinofilik qastro\u00aden\u00adterit v\u0259 xoral\u0131 kolit zaman\u0131 qan\u00addak\u0131 eozinofill\u0259rin \u00fcmumi say\u0131 art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ER\u0130TROS\u0130T SAYI<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Q\u0131rm\u0131z\u0131 qan h\u00fcceyr\u0259\u00adl\u0259\u00adrinin say\u0131; RBC<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admu\u00adn\u0259 al\u0131nark\u0259n turnan\u0131n uzun m\u00fcd\u00add\u0259t qalmas\u0131 s\u0259hv n\u0259tic\u0259l\u0259r\u0259 s\u0259b\u0259b olur<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Saat 17.00-07.00 aras\u0131nda v\u0259 yem\u0259kl\u0259rd\u0259n sonra\u00a0 eritrositl\u0259rin say\u0131nda bir q\u0259d\u0259r\u00a0 azalma m\u00fc\u015fahid\u0259 oluna bil\u0259r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0H\u00fcceyr\u0259 say\u0131lmas\u0131<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0N\u00fc\u00admun\u0259nin laxtalanm\u0131\u015f olmas\u0131<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259sind\u0259n g\u00f6t\u00fcr\u00fclm\u00fc\u015f qan<\/td>\n3.9-5.5 milyon\/mm3<\/sup><\/td>\n<\/tr>\n
Erk\u0259n do\u011fulmu\u015f u\u015faqlarda<\/td>\n3.9-5.5 milyon\/mm3<\/sup><\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n4.0-6.6 milyon\/mm3<\/sup><\/td>\n<\/tr>\n
7 g\u00fcn-1 ay<\/td>\n3.9-6.2 milyon\/mm3<\/sup><\/td>\n<\/tr>\n
2-3 ay<\/td>\n3.0-5.4 milyon\/mm3<\/sup><\/td>\n<\/tr>\n
4-6 ay<\/td>\n3.1-4.5 milyon\/mm3<\/sup><\/td>\n<\/tr>\n
7 ay-3 ya\u015f<\/td>\n3.7-5.3 milyon\/mm3<\/sup><\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n3.9-5.3 milyon\/mm3<\/sup><\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n4.0-5.2 milyon\/mm3<\/sup><\/td>\n<\/tr>\n
\u00a0<\/strong><\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n4.5-5.3 milyon\/mm3<\/sup><\/td>\n4.1-5.1 milyon\/mm3<\/sup><\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n4.5-5.9 milyon\/mm3<\/sup><\/td>\n4.0-5.2 milyon\/mm3<\/sup><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Polisitemiya, a\u011f\u0131r idman, hemokonsentrasiya v\u0259 y\u00fcks\u0259k\u00adlik\u00adl\u0259r\u00add\u0259 eritrositl\u0259rin say\u0131 art\u0131r, anemiyalar v\u0259 hemoliz\u0259 s\u0259b\u0259b olan b\u0259zi d\u0259rman\u00adlar\u0131n q\u0259bulu zaman\u0131 is\u0259 eritrositl\u0259rin say\u0131 azala bil\u0259r. Bunlardan ba\u015fqa, so\u00adyuq aqql\u00fctininl\u0259rin varl\u0131\u011f\u0131 da yaln\u0131\u015f olaraq eritrositin say\u0131n\u0131n azl\u0131\u011f\u0131na v\u0259 ya avtomatik qan say\u0131m cihazlar\u0131nda say\u0131lmamas\u0131na s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ER\u0130TROS\u0130TL\u018fR\u0130N \u00c7\u00d6KM\u018f S\u00dcR\u018fT\u0130<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Sedimentasiya; Western \u00e7\u00f6km\u0259 s\u00fcr\u0259ti; ESR, E\u00c7S<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Qara qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01.5 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Qapal\u0131 sistem<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0N\u00fc\u00admu\u00adn\u0259nin laxtal\u0131, hemolizli v\u0259 ya h\u0259d\u00addind\u0259n art\u0131q lipemiyal\u0131 olmas\u0131, uzun m\u00fcdd\u0259t g\u00f6zl\u0259m\u0259si, qan\/sitrat nisb\u0259\u00adtinin d\u00fczg\u00fcn olmamas\u0131 v\u0259 miqda\u00adr\u0131\u00adn\u0131n laz\u0131m olandan az v\u0259 ya \u00e7ox olmas\u0131<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n
Ya\u015f<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
<7g\u00fcn<\/td>\n<10mm\/saat<\/td>\n<10mm\/saat<\/td>\n<\/tr>\n
7g\u00fcn-50ya\u015f<\/td>\n<15mm\/saat<\/td>\n<20mm\/saat<\/td>\n<\/tr>\n
>50ya\u015f<\/td>\n<20mm\/saat<\/td>\n<25mm\/saat<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u0130ltihabi x\u0259st\u0259likl\u0259r, k\u0259skin v\u0259 xroniki infksiyalar, toxuma nek\u00adro\u00adzu, temporal arterit, b\u0259d xass\u0259li t\u00f6r\u0259m\u0259l\u0259r, revmatoid x\u0259st\u0259likl\u0259r v\u0259 autoimmun x\u0259st\u0259likl\u0259rin diaqnoz v\u0259 m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ESR (ER\u0130TROS\u0130TL\u018fR\u0130N \u00c7\u00d6KM\u018f S\u00dcR\u018fT\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Sedimentasiya; Western \u00e7\u00f6km\u0259 s\u00fcr\u0259ti; ESR, E\u00c7S<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Qara qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01.5 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Qapal\u0131 sistem<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0N\u00fc\u00admu\u00adn\u0259nin laxtal\u0131, hemolizli v\u0259 ya h\u0259d\u00addind\u0259n art\u0131q lipemiyal\u0131 olmas\u0131, uzun m\u00fcdd\u0259t g\u00f6zl\u0259m\u0259si, qan\/sitrat nisb\u0259\u00adtinin d\u00fczg\u00fcn olmamas\u0131 v\u0259 miqda\u00adr\u0131\u00adn\u0131n laz\u0131m olandan az v\u0259 ya \u00e7ox olmas\u0131<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n
Ya\u015f<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
<7g\u00fcn<\/td>\n<10mm\/saat<\/td>\n<10mm\/saat<\/td>\n<\/tr>\n
7g\u00fcn-50ya\u015f<\/td>\n<15mm\/saat<\/td>\n<20mm\/saat<\/td>\n<\/tr>\n
>50ya\u015f<\/td>\n<20mm\/saat<\/td>\n<25mm\/saat<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u0130ltihabi x\u0259st\u0259likl\u0259r, k\u0259skin v\u0259 xroniki infksiyalar, toxuma nek\u00adro\u00adzu, temporal arterit, b\u0259d xass\u0259li t\u00f6r\u0259m\u0259l\u0259r, revmatoid x\u0259st\u0259likl\u0259r v\u0259 autoimmun x\u0259st\u0259likl\u0259rin diaqnoz v\u0259 m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

EUQLOB\u0130N TROMB L\u0130Z\u0130S<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Fibrinoliz zaman\u0131<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratli plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (natrium sitrat\u0131n miqdar\u0131 nor\u00admadan iki d\u0259f\u0259 \u00e7ox olmal\u0131d\u0131r)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admu\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admo\u00adliz\u0259 u\u011framadan d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0X\u0259st\u0259 qan verm\u0259zd\u0259n \u0259vv\u0259l idman h\u0259r\u0259k\u0259tl\u0259ri etm\u0259m\u0259lidir<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0N\u00fc\u00admun\u0259ni iki saat m\u00fcdd\u0259tind\u0259 laborato\u00adriyaya \u00e7atd\u0131r\u0131lmamas\u0131, uy\u011fun olma\u00adyan qan\/antikoaqulyant nisb\u0259ti (n\u00fc\u00admu\u00adn\u0259d\u0259ki sitrat nisb\u0259tinin ikiqat ol\u00admamas\u0131), laxtalanm\u0131\u015f, hemolizli, he\u00adparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:<\/strong>\u00a0Tromb lizisi 2-4 saata ba\u015f verir<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Urekinaza v\u0259 sterpto\u00adkinaza m\u00fcalic\u0259si il\u0259 fibrinolitik ak\u00adtivliyin m\u00fc\u015fahid\u0259si v\u0259 anormal fibri\u00adnolizisin m\u00fcayin\u0259sind\u0259 istifad\u0259 olu\u00adnur. S\u00fcr\u0259tli lizis y\u00fcks\u0259k fibrinolitik aktivliyi g\u00f6st\u0259rir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FAKTOR I (F\u0130BR\u0130NOGEN)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>I Faktor<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fcmu\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma hemoliz\u0259 u\u011framadan tez ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259\u00adraitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan qan\/antikoaqulyant nis\u00adb\u0259\u00adti, laxtal\u0131, hemolizli, heparinli n\u00fcmu\u00adn\u0259l\u0259r<\/p>\n

Referens:\u00a0<\/strong>2.0-4.5 g\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Fibrinogen k\u0259skin faza re\u00adaktantlar\u0131ndan biridir. Anadan\u00adg\u0259l\u00adm\u0259 afibrinogenemiya, hipofibrino\u00adge\u00adnemiya, disfibrinogenemiya, disse\u00admi\u00ad\u00adnasiya olunan damardaxili laxta\u00adlanma, k\u0259skin a\u011fciy\u0259r emboliyas\u0131, sistemik fibrinoliz, pankreatit v\u0259 a\u011f\u0131r qaraciy\u0259r \u00e7at\u0131\u015fmazl\u0131\u011f\u0131nda fibrinogen miqdar\u0131 azal\u0131r; infeksiyalar, ha\u00admi\u00adl\u0259lik, travma v\u0259 yay\u0131lm\u0131\u015f toxuma nekro\u00adzunda is\u0259 bu g\u00f6st\u0259rici art\u0131r. Y\u00fcks\u0259k fibrinogen s\u0259viyy\u0259si trom\u00adboz riskini art\u0131rd\u0131\u011f\u0131ndan kardiovas\u00adkulyar x\u0259st\u0259likl\u0259r v\u0259 iflic riski d\u0259\u00a0 art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FAKTOR II<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Protrombin aktivliyi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratli plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fcm\u00adun\u0259 al\u0131nd\u0131qdan sonra plazma hemo\u00adliz\u0259 u\u011framadan tez ayr\u0131lmal\u0131 v\u0259 so\u00adyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:\u00a0<\/strong>Risk qiy\u00adm\u0259tl\u0259ndirilm\u0259si apar\u0131ld\u0131qdan sonra komadin cinsli antikoaqulyant isti\u00adfad\u0259 ed\u0259n x\u0259st\u0259l\u0259r 2 h\u0259ft\u0259, heparin m\u00fca\u00adlic\u0259si alanlar is\u0259 2 g\u00fcn \u0259vv\u0259ld\u0259n m\u00fcalic\u0259ni dayand\u0131rmal\u0131d\u0131rlar<\/p>\n

\u0130\u015f prinsipi:<\/strong>Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>\u00a0Uy\u00ad\u011fun olmayan qan\/antikoaqulyant nisb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:\u00a0<\/strong>Normal aktivliyin 50-150 %-i<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Protrombin zaman\u0131 il\u0259 ey\u00adni test kimi qiym\u0259tl\u0259ndirilm\u0259\u00adm\u0259\u00adlidir. \u0130rsi protrombin \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 ol\u00adduqca nadir rast g\u0259lin\u0259n koaquli\u00adya\u00adsiya poz\u00ad\u011funlu\u011fudur. Autosom reses\u00adsiv me\u00adxa\u00adnizml\u0259 ke\u00e7\u0259n bu poz\u011funluq zaman\u0131 orqanizmd\u0259 m\u00fct\u0259lif d\u0259r\u0259c\u0259l\u0259rd\u0259 qan\u00adaxmaya meyillik olur. Bu \u015f\u0259xsl\u0259rd\u0259 PT v\u0259 aPTT testl\u0259rind\u0259 uzanma m\u00fc\u00ad\u015fahid\u0259 edilir. H\u0259m\u00e7inin K vitamini \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 v\u0259 oral antikoaquliyant m\u00fcalic\u0259si protrombin s\u0259viyy\u0259l\u0259rini azald\u0131r. Protrombin s\u0259viyy\u0259l\u0259rinin y\u00fcks\u0259kliyi is\u0259 protrombin genind\u0259ki mutasiyan\u0131n n\u0259tic\u0259si kimi inki\u015faf edir v\u0259 tromboz riskini art\u0131r\u0131r. Bel\u0259 hallarda x\u0259st\u0259d\u0259 kardiovaskulyar risk faktorlar\u0131 da varsa, miokard infarkt\u0131 eh\u00adtimal\u0131 art\u0131r. 115% aktivlikd\u0259n yu\u00adxar\u0131 n\u0259tic\u0259l\u0259r is\u0259 risk kimi q\u0259bul edilmir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FAKTOR IX<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Anti-hemofiliya faktoru B; Christmas faktoru; Autoprotrombin II<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admu\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admo\u00adliz\u0259 u\u011framadan tez ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Risk qiy\u00adm\u0259t\u00adl\u0259ndirm\u0259 apar\u0131ld\u0131qdan sonra ku\u00admadin cinsli antikoaqulyant istifad\u0259 ed\u0259n x\u0259s\u00adt\u0259l\u0259rd\u0259 2 h\u0259ft\u0259, heparin m\u00fca\u00adlic\u0259sind\u0259 is\u0259 2 g\u00fcn \u0259vv\u0259l m\u00fcalic\u0259 k\u0259silm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>Kaoqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan qan\/antikoaqulyant nis\u00adb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fc\u00admun\u0259l\u0259r<\/p>\n

Referens:\u00a0<\/strong>Normal aktivliyin 50-150%-i<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u0130rsi IX faktorun \u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u011f\u0131 (hemofiliya B), \u201cX\u201d il\u0259 \u0259laq\u0259li ke\u00e7\u0259n, qanaxma diatezi v\u0259 plazmada IX faktor aktivliyinin az olmas\u0131 il\u0259 xarakteriz\u0259 olunan x\u0259st\u0259likdir. \u018fsa\u00ads\u0259n ki\u015fil\u0259rd\u0259 rast g\u0259linir, qad\u0131nlar is\u0259 da\u015f\u0131y\u0131c\u0131d\u0131r. 1\/25000 tezliyind\u0259\u00a0 rast g\u0259\u00adlinir. Bu x\u0259st\u0259l\u0259rd\u0259 APTT uzan\u0131r, PT normal olur.\u00a0 Qazan\u0131lm\u0131\u015f IX fak\u00adtor \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 is\u0259 oral anti\u00adkoa\u00adqul\u00adyantlar\u0131n istifad\u0259si, a\u011f\u0131r qaraciy\u0259r x\u0259s\u00adt\u0259liyi v\u0259 K vitamini \u00e7at\u0131\u015fmaz\u00adl\u0131\u011f\u0131nda m\u00fc\u015fahid\u0259 oluna bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FAKTOR IX \u0130NH\u0130B\u0130TOR<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra plazma hemoliz\u0259 u\u011framadan tez ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>Kaoqulometrik<\/p>\n

Referens:\u00a0<\/strong>N\u0259tic\u0259d\u0259 bildirilir<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Faktor \u0259v\u0259zedici m\u00fcalic\u0259 alanlarda v\u0259 ya spontan olaraq (do\u00ad\u011fu\u015fdan sonra, immunoloji x\u0259st\u0259\u00adlik\u00adl\u0259r, antibiotik istifad\u0259si, b\u0259d xass\u0259li t\u00f6r\u0259m\u0259l\u0259r, qocal\u0131q) faktor inhi\u00adbi\u00adtor\u00adlar\u0131 \u0259m\u0259l\u0259 g\u0259lir v\u0259 m\u00fcvafiq faktorlar\u0131 inhibisiya edir. Bu test il\u0259 IX faktor inhibitorunun varl\u0131\u011f\u0131 ara\u015fd\u0131r\u0131l\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FAKTOR V<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>AC globulin; Labil faktor; Plazma akselerator globulin; Pro\u00adakselerin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan qan\/antikoaqulyant nis\u00adb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fc\u00admun\u0259l\u0259r<\/p>\n

Referens:<\/strong>\u00a0Normal aktivliyin\u00a0 50-150 %-i<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>V faktorun\u00a0 irsi \u00e7at\u0131\u00ad\u015f\u00admaz\u00adl\u0131\u011f\u0131 olan x\u0259st\u0259l\u0259rd\u0259 (parahe\u00admofiliya) anormal qanaxmalar m\u00fc\u015fahid\u0259 olu\u00adnur v\u0259 laxtalanma zaman\u0131, PT v\u0259 APTT testl\u0259rind\u0259 uzanmalar m\u00fc\u0259y\u00ady\u0259n edilir. Hamil\u0259lik zaman\u0131 bir s\u0131ra laxtalanma faktorlar\u0131 kimi V faktor\u00adda da az miqdarda art\u0131m ba\u015f ver\u0259 bil\u0259r. K\u0259skin qaraciy\u0259r \u00e7at\u0131\u015fmazl\u0131\u00ad\u011f\u0131nda sintezin z\u0259ifl\u0259m\u0259si, DDL za\u00adman\u0131 is\u0259 s\u0259rf olunman\u0131n artmas\u0131 il\u0259 \u0259laq\u0259dar olaraq V faktorun miqdar\u0131 azal\u0131r. V faktorun t\u0259yini qaraciy\u0259r x\u0259st\u0259liyi v\u0259 K vitamini \u00e7at\u0131\u015fmaz\u00adl\u0131\u011f\u0131n\u0131n differensiasiyas\u0131nda istifad\u0259 olunur. Parenximal qaraciy\u0259r x\u0259st\u0259\u00adlik\u00adl\u0259rind\u0259 V faktor v\u0259 K vita\u00admi\u00adnin\u00add\u0259n as\u0131l\u0131 sintez olunan laxtalanma faktorlar\u0131 (II, VII, IX v\u0259 X faktorlar) azald\u0131\u011f\u0131 halda, K vitamini \u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u011f\u0131nda V faktor normal, dig\u0259r fak\u00adtorlar\u0131n miqdar\u0131 is\u0259 a\u015fa\u011f\u0131 olur. Bu m\u0259q\u00ads\u0259dl\u0259 V v\u0259 VII faktorlar\u0131n aktiv\u00adliyi t\u0259yin oluna bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FAKTOR VII<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Autoprotrombin I; Pro\u00adkon\u00advertin; Stabil faktor\u00a0<\/strong><\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan tez ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:\u00a0<\/strong>Risk qiym\u0259t\u00adl\u0259ndirilm\u0259si apar\u0131ld\u0131qdan son\u00adra ku\u00adma\u00addin cinsli antikoaqulyant istifad\u0259 ed\u0259n x\u0259s\u00adt\u0259l\u0259rd\u0259 2 h\u0259ft\u0259, heparin m\u00fcali\u00adc\u0259\u00adsin\u00add\u0259 is\u0259 2 g\u00fcn \u0259vv\u0259l m\u00fcalic\u0259 k\u0259silm\u0259\u00adlidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Kaoqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>Uy\u00ad\u011fun olmayan qan\/antikoaqulyant nis\u00adb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:\u00a0<\/strong>Normal aktivliyin 50-150%-i<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>VII faktorun \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, nadir rast g\u0259lin\u0259n, autosom resessiv ke\u00e7\u0259n irsi x\u0259st\u0259likdir. X\u0259st\u0259lik olan \u015f\u0259xsl\u0259rd\u0259 PT uzan\u0131r, APTT is\u0259 nor\u00admal olur. Klinik qanaxman\u0131n \u015fidd\u0259ti VII faktorun aktivlik s\u0259viyy\u0259si il\u0259 \u0259la\u00adq\u0259\u00addard\u0131r. Qaraciy\u0259r x\u0259st\u0259liyi v\u0259 K vita\u00admini \u00e7at\u0131\u015fmazn\u0131\u011f\u0131n\u0131n differen\u00adsiasi\u00adya\u00ads\u0131ndada istifad\u0259 olunur. Pa\u00adrenximal qaraciy\u0259r x\u0259st\u0259likl\u0259rind\u0259 V faktor v\u0259 K vitaminind\u0259n as\u0131l\u0131 sintez olunan lax\u00adta\u00adlanma faktorlar\u0131 (II, VII, IX v\u0259 X) azal\u00add\u0131\u011f\u0131 halda, K vitamini \u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u011f\u0131nda V faktor normal, di\u00adg\u0259r faktor s\u0259viyy\u0259l\u0259ri is\u0259 a\u015fa\u011f\u0131 olur. Bu m\u0259qs\u0259dl\u0259 V v\u0259 VII faktorlar\u0131n ak\u00adtivliyi t\u0259yin oluna bil\u0259r. Oral kon\u00adtraseptiv istifad\u0259 ed\u0259n qad\u0131nlar\u0131n plazmalar\u0131 4o<\/sup>C-d\u0259 sax\u00adlan\u0131ld\u0131qda VII faktorun aktivliyind\u0259 10 d\u0259f\u0259y\u0259 q\u0259\u00add\u0259r art\u0131m m\u00fc\u015fahid\u0259 oluna bil\u0259r. H\u0259m\u00ad\u00e7inin VII faktorun aktiv\u00adliyinin artmas\u0131 miokard infarkt\u0131 riskini d\u0259 art\u0131r\u0131r. Oral antikoaqulyantlar\u0131n is\u00adtifad\u0259si, a\u011f\u0131r qaraciy\u0259r x\u0259st\u0259liyi v\u0259 K vitamini \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 hallar\u0131nda is\u0259 VII faktorun s\u0259viyy\u0259sind\u0259 azalmalar m\u00fc\u00ad\u015fahid\u0259 oluna bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FAKTOR VIII<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Antihemofiliya faktoru<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan tez ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Risk qiy\u00adm\u0259t\u00adl\u0259ndirilm\u0259si apar\u0131ld\u0131qdan sonra heparin m\u00fcalic\u0259si m\u00fcayin\u0259d\u0259n 2 g\u00fcn \u0259vv\u0259l k\u0259silm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Kaoqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan qan\/anti\u00adkoa\u00adqul\u00adyant\u00adnisb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:\u00a0<\/strong>Normal aktivliyin 50-150 %-i<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u0130rsi VIII faktorun \u00e7at\u0131\u015f\u00admazl\u0131\u011f\u0131 (hemofiliya A) X-\u0259 ba\u011fl\u0131 ke\u00e7\u0259n v\u0259 qanaxmaya meyillilikl\u0259 xa\u00adrakteriz\u0259 olunan x\u0259st\u0259likdir. Klinik olaraq VIII faktorun \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, x\u0259s\u00adt\u0259nin plazmas\u0131nda VIII faktorun s\u0259viyy\u0259sind\u0259n as\u0131l\u0131 olaraq, \u015fidd\u0259tli (<1%), orta d\u0259r\u0259c\u0259 (1-5%) v\u0259 y\u00fcng\u00fcl (>5%) d\u0259r\u0259c\u0259l\u0259r\u0259 ayr\u0131l\u0131r. H\u0259min \u015f\u0259xs\u00ad\u00adl\u0259rd\u0259 aPTT uzand\u0131\u011f\u0131 halda, PT v\u0259 TT normal olur. H\u0259m\u00e7inin VIII faktor k\u0259skin faza reaktant\u0131 olub, esterogenl\u0259rin istifad\u0259si, qaraciy\u0259r x\u0259st\u0259liyi, \u015f\u0259k\u0259rli diabet, stress hallar\u0131 v\u0259 ya idman h\u0259r\u0259k\u0259tl\u0259rind\u0259n sonra y\u00fcks\u0259l\u0259 bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FAKTOR VIII \u0130L\u018f \u018fLAQ\u018fL\u0130 ANT\u0130GEN (VON W\u0130LLEBREND FAKTOR ANT\u0130GEN\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Faktor VIII il\u0259 \u0259laq\u0259di antigen<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u011fun olmayan qan\/antikoaqulyant nisb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:<\/strong>\u00a060-150%<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Qazan\u0131lm\u0131\u015f v\u0259 ya kon\u00adgenital von Willerbrand x\u0259st\u0259liyinin (vWD) t\u0259yini, hemofiliya A il\u0259 differensasiyas\u0131nda v\u0259 vWD-li x\u0259st\u0259\u00adl\u0259r\u0259 t\u0259tbiq olunan m\u00fcalic\u0259nin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FAKTOR VIII \u0130NH\u0130B\u0130TOR<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admu\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan tez ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Kaoqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan qan\/antikoaqul\u00adyan\u00adtnis\u00adb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fc\u00admun\u0259l\u0259r<\/p>\n

Referens:<\/strong>\u00a0<0.9 Bethesda vahidi<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Faktor \u0259v\u0259zedici m\u00fcalic\u0259 alan \u015f\u0259xsl\u0259rd\u0259 v\u0259 ya spontan olaraq (do\u011fu\u015fdan sonra, immunoloji x\u0259s\u00adt\u0259\u00adlik\u00adl\u0259r, antibiotik istifad\u0259si, b\u0259d xas\u00ads\u0259li t\u00f6r\u0259m\u0259l\u0259r, qocal\u0131q) faktor inhi\u00adbi\u00adtorlar\u0131 \u0259m\u0259l\u0259 g\u0259lir v\u0259 m\u00fcvafiq fak\u00adtor\u00adlar\u0131 inhibisiya edir. Bu test il\u0259 VIII fak\u00adtor inhibitorunun varl\u0131\u011f\u0131 ara\u015f\u00add\u0131\u00adr\u0131l\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FAKTOR X<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Stuart faktoru; auto\u00adpro\u00adtrombin C; autoprotrombin III<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admu\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan tez ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Risk qiy\u00adm\u0259tl\u0259ndirilm\u0259 apar\u0131ld\u0131qdan sonra ku\u00admadin cinsli antikoaqulyant istifad\u0259 ed\u0259n x\u0259st\u0259l\u0259rd\u0259 2 h\u0259ft\u0259, heparin m\u00fca\u00adli\u00adc\u0259\u00adsind\u0259 is\u0259 2 g\u00fcn \u0259vv\u0259l m\u00fca\u00adlic\u0259 k\u0259silm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan qan\/antikoaqul\u00adyant\u00adnisb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:\u00a0<\/strong>Normal aktivliyin 50-150%-i<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u0130rsi X faktor \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 olan x\u0259st\u0259l\u0259rd\u0259 PT v\u0259 APTT uzanm\u0131\u015f, TT is\u0259 normald\u0131r. X faktor \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 autosom resessiv ke\u00e7ir. Qazan\u0131lm\u0131\u015f X faktor \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 is\u0259 birincili amiloidoz il\u0259 \u0259laq\u0259dard\u0131r. Bundan ba\u015fqa, oral antikoaqul\u00adyant\u00adlar\u0131n istifad\u0259si v\u0259 K vitamini \u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u011f\u0131nda da X faktorun miqdar\u0131 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FAKTOR XI<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Plazma tromboplastin an\u00adte\u00adsedan<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan tez ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Risk qiy\u00adm\u0259t\u00adl\u0259ndirm\u0259 apar\u0131ld\u0131qdan sonra he\u00adparin m\u00fcalic\u0259si m\u00fcayin\u0259d\u0259n 2 g\u00fcn \u0259vv\u0259l k\u0259silm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u011fun olmayan qan\/antikoaqulyant nisb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n
Normal aktivliyin %-i<\/td>\n<7g\u00fcn<\/td>\n20-50<\/td>\n<\/tr>\n
7g\u00fcn-1ay<\/td>\n25-70<\/td>\n<\/tr>\n
2-3ay<\/td>\n40-100<\/td>\n<\/tr>\n
4-6ay<\/td>\n50-130<\/td>\n<\/tr>\n
>60ay<\/td>\n50-150<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

trong>\u0130stifad\u0259si: Homoziqot XI faktor \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 olan x\u0259st\u0259l\u0259rd\u0259 laxtalanma zaman\u0131 v\u0259 APTT uzan\u0131r, d\u0259yi\u015fk\u0259n qanaxma m\u0259nz\u0259r\u0259si m\u00fc\u015fahid\u0259 olunur. PT, TT, trombosit say\u0131 v\u0259 trombositl\u0259rin funksional testl\u0259ri is\u0259 normald\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FAKTOR XII<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Hageman faktoru<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fcmun\u0259 al\u0131nd\u0131qdan sonra plazma hemoliz\u0259 u\u011framadan tez ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Risk qiym\u0259tl\u0259ndirm\u0259 apar\u0131ld\u0131qdan sonra heparin m\u00fcalic\u0259si m\u00fcayin\u0259d\u0259n 2 g\u00fcn \u0259vv\u0259l k\u0259silm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan qan\/antikoaqulyant nis\u00adb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n
Normal aktivliyin %-i<\/td>\n<7g\u00fcn<\/td>\n25-50<\/td>\n<\/tr>\n
7g\u00fcn-1ay<\/td>\n30-70<\/td>\n<\/tr>\n
2-3ay<\/td>\n40-100<\/td>\n<\/tr>\n
4-6ay<\/td>\n50-130<\/td>\n<\/tr>\n
>60ay<\/td>\n50-150<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u0130rsi XII faktor \u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u011f\u0131 olan x\u0259st\u0259l\u0259rin \u0259ks\u0259riyy\u0259tind\u0259 qan\u00adaxma probleml\u0259ri olmad\u0131\u011f\u0131 hal\u00adda, trombembolik probleml\u0259r daha \u00e7ox rast g\u0259linir. Bu x\u0259st\u0259l\u0259rd\u0259 PT normal, APTT uzanm\u0131\u015f olur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FAKTOR XIII SKR\u0130N\u0130NQ<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Fibrin stabill\u0259\u015fdirici faktor<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admu\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admo\u00adliz\u0259 u\u011framadan tez ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Tromb lizis<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan qan\/antikoaqul\u00adyant\u00adnisb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>XIII faktorun \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 autosom resessiv ke\u00e7ir. X\u0259st\u0259l\u0259rd\u0259 ilk qanaxma hadis\u0259si g\u00f6b\u0259k ciy\u0259si ay\u00adr\u0131l\u00add\u0131qdan sonra ba\u015f verir. Bu x\u0259s\u00adt\u0259l\u0259rd\u0259 \u00fcmumi hemostaz testl\u0259ri normalk\u0259n, travma sonras\u0131 \u0259m\u0259l\u0259 g\u0259l\u0259n yaralar gec sa\u011fal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

F\u0130BR\u0130N PAR\u00c7ALANMA M\u018fHSULLARI (D-D\u0130MER)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Fibrinin par\u00e7alanma m\u0259h\u00adsullar\u0131<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250\u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0N\u00fc\u00admu\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admo\u00adliz\u0259 u\u011framadan tez ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u011fun olmayan s\u0131naq \u015f\u00fc\u015f\u0259si v\u0259 qan\/antikoagulyant nisb\u0259ti, laxtal\u0131, hemolizli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:<\/strong>\u00a0<10-150 \u03bcg\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0D-Dimer s\u0259viyy\u0259sinin normadan y\u00fcks\u0259k olmas\u0131 laxtalanma, bel\u0259likl\u0259 d\u0259rin vena trombozu, a\u011f\u00adci\u00ady\u0259r emboliyas\u0131 v\u0259 ya DDL (disse\u00admi\u00adn\u0259 olunmu\u015f damardaxili laxtalanma) (disseminated intravascular coagu\u00adla\u00adtion, DIC) ehtimal\u0131n\u0131 art\u0131r\u0131r. Bundan ba\u015fqa, yumurtal\u0131q karsinomalar\u0131 v\u0259 b\u00f6yr\u0259k x\u0259st\u0259lik\u0259rind\u0259 fibrinin par\u00e7a\u00adlanmas\u0131n\u0131n t\u0259yinind\u0259, d\u0259rin vena trom\u00adbozu v\u0259 ya k\u0259skin miokard in\u00adfakt\u0131 zaman\u0131 apar\u0131lan m\u00fcalic\u0259nin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

F\u0130BR\u0130N STAB\u0130LL\u018f\u015eT\u0130R\u0130C\u0130 FAKTOR (FAKTOR XIII SKR\u0130N\u0130NQ)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Fibrin stabill\u0259\u015fdirici faktor<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admu\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admo\u00adliz\u0259 u\u011framadan tez ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Tromb lizis<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan qan\/antikoaqul\u00adyant\u00adnisb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>XIII faktorun \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 autosom resessiv ke\u00e7ir. X\u0259st\u0259l\u0259rd\u0259 ilk qanaxma hadis\u0259si g\u00f6b\u0259k ciy\u0259si ay\u00adr\u0131l\u00add\u0131qdan sonra ba\u015f verir. Bu x\u0259s\u00adt\u0259l\u0259rd\u0259 \u00fcmumi hemostaz testl\u0259ri normalk\u0259n, travma sonras\u0131 \u0259m\u0259l\u0259 g\u0259l\u0259n yaralar gec sa\u011fal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

F\u0130BR\u0130NOGEN<\/a><\/h2>\r\n
\r\n
\r\n <\/p>\n
F\u0130BR\u0130NOGEN<\/a><\/h5>\n
\n
\n

Sinonim:\u00a0<\/strong>I Faktor<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fcmu\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma hemoliz\u0259 u\u011framadan tez ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259\u00adraitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan qan\/antikoaqulyant nis\u00adb\u0259\u00adti, laxtal\u0131, hemolizli, heparinli n\u00fcmu\u00adn\u0259l\u0259r<\/p>\n

Referens:\u00a0<\/strong>2.0-4.5 g\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Fibrinogen k\u0259skin faza re\u00adaktantlar\u0131ndan biridir. Anadan\u00adg\u0259l\u00adm\u0259 afibrinogenemiya, hipofibrino\u00adge\u00adnemiya, disfibrinogenemiya, disse\u00admi\u00ad\u00adnasiya olunan damardaxili laxta\u00adlanma, k\u0259skin a\u011fciy\u0259r emboliyas\u0131, sistemik fibrinoliz, pankreatit v\u0259 a\u011f\u0131r qaraciy\u0259r \u00e7at\u0131\u015fmazl\u0131\u011f\u0131nda fibrinogen miqdar\u0131 azal\u0131r; infeksiyalar, ha\u00admi\u00adl\u0259lik, travma v\u0259 yay\u0131lm\u0131\u015f toxuma nekro\u00adzunda is\u0259 bu g\u00f6st\u0259rici art\u0131r. Y\u00fcks\u0259k fibrinogen s\u0259viyy\u0259si trom\u00adboz riskini art\u0131rd\u0131\u011f\u0131ndan kardiovas\u00adkulyar x\u0259st\u0259likl\u0259r v\u0259 iflic riski d\u0259\u00a0 art\u0131r<\/p>\n<\/div>\n<\/div>\n

\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

F\u0130BR\u0130NOL\u0130Z ZAMANI (EUQLOB\u0130N TROMB L\u0130Z\u0130S)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Fibrinoliz zaman\u0131<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratli plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (natrium sitrat\u0131n miqdar\u0131 nor\u00admadan iki d\u0259f\u0259 \u00e7ox olmal\u0131d\u0131r)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admu\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admo\u00adliz\u0259 u\u011framadan d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0X\u0259st\u0259 qan verm\u0259zd\u0259n \u0259vv\u0259l idman h\u0259r\u0259k\u0259tl\u0259ri etm\u0259m\u0259lidir<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0N\u00fc\u00admun\u0259ni iki saat m\u00fcdd\u0259tind\u0259 laborato\u00adriyaya \u00e7atd\u0131r\u0131lmamas\u0131, uy\u011fun olma\u00adyan qan\/antikoaqulyant nisb\u0259ti (n\u00fc\u00admu\u00adn\u0259d\u0259ki sitrat nisb\u0259tinin ikiqat ol\u00admamas\u0131), laxtalanm\u0131\u015f, hemolizli, he\u00adparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:<\/strong>\u00a0Tromb lizisi 2-4 saata ba\u015f verir<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Urekinaza v\u0259 sterpto\u00adkinaza m\u00fcalic\u0259si il\u0259 fibrinolitik ak\u00adtivliyin m\u00fc\u015fahid\u0259si v\u0259 anormal fibri\u00adnolizisin m\u00fcayin\u0259sind\u0259 istifad\u0259 olu\u00adnur. S\u00fcr\u0259tli lizis y\u00fcks\u0259k fibrinolitik aktivliyi g\u00f6st\u0259rir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

F\u0130NRONEKT\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>FN<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 plazma, maye<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (plazma), gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si (maye)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Nefelometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admo\u00adliz, lipemiya<\/p>\n

Referens:\u00a0<\/strong>Serum 0.05-0.50 g\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Sinovial mayed\u0259ki fibri\u00adnoektinin konsentrasiyas\u0131 serumda\u00adk\u0131ndan y\u00fcks\u0259k olur.<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FN (F\u0130NRONEKT\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>FN<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 plazma, maye<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (plazma), gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si (maye)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Nefelometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admo\u00adliz, lipemiya<\/p>\n

Referens:\u00a0<\/strong>Serum 0.05-0.50 g\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Sinovial mayed\u0259ki fibri\u00adnoektinin konsentrasiyas\u0131 serumda\u00adk\u0131ndan y\u00fcks\u0259k olur.<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

G6PD (QL\u00dcKOZA-6-FOSFAT DEH\u0130DROGENAZA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>G6PD<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>500 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, ki\u00adnetik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
<1 ya\u015f<\/td>\n6.5-14.4 U\/g Hb<\/td>\n<\/tr>\n
>1 ya\u015f<\/td>\n4.6-13.5 U\/g Hb<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0G6PD \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 il\u0259 \u0259la\u00adq\u0259dar inki\u015faf ed\u0259n hemolitik ane\u00admi\u00adyalar\u0131n t\u0259yinind\u0259 istifad\u0259 olur. G\u0259nc eritrositl\u0259rd\u0259 G6PD ak\u00adtivliyi y\u00fcks\u0259k oldu\u011fundan he\u00admo\u00adlitik epi\u00adzod\u00addan sonra \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 t\u0259yini \u0259k\u00ads\u0259r hallarda m\u00fcmk\u00fcn olmur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HB (HEMOQLOB\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Hb<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>1 mL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>H\u00fcceyr\u0259 say\u0131lmas\u0131 (Cell counter)<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0N\u00fc\u00admun\u0259nin laxtalanm\u0131\u015f olmas\u0131<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259si qan\u0131<\/td>\n13.5-20.0 g\/dL<\/td>\n<\/tr>\n
Erk\u0259n do\u011fulmu\u015f u\u015faqlarda<\/td>\n13.5-20.0 g\/dL<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n14.5-22.5 g\/dL<\/td>\n<\/tr>\n
7 g\u00fcn-1 ay<\/td>\n13.5-20.5 g\/dL<\/td>\n<\/tr>\n
<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
2-3 ay<\/td>\n10.0-14.5 g\/dL<\/td>\n10.0-14.0 g\/dL<\/td>\n<\/tr>\n
4-6 ay<\/td>\n9.5-13.5 g\/dL<\/td>\n9.5-13.5 g\/dL<\/td>\n<\/tr>\n
7 ay-3 ya\u015f<\/td>\n10.5-13.5 g\/dL<\/td>\n10.5-13.5 g\/dL<\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n11.5-13.5 g\/dL<\/td>\n11.5-13.5 g\/dL<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n11.5-15.5 g\/dL<\/td>\n11.5-15.5 g\/dL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n13.0-16.0 g\/dL<\/td>\n12.0-16.0 g\/dL<\/td>\n<\/tr>\n
16-50 ya\u015f<\/td>\n13.5-17.5 g\/dL<\/td>\n12.0-16.0 g\/dL<\/td>\n<\/tr>\n
>50 ya\u015f<\/td>\n14.0-18.0 g\/dL<\/td>\n13.0-17.0 g\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Anemiya, qan itkisi, po\u00adlistemiya v\u0259 dig\u0259r v\u0259ziyy\u0259tl\u0259rin qiy\u00adm\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olunur. Polistemiya, idman, hemokon\u00adsentra\u00adsiya (dehidratasiya, yan\u0131q, h\u0259dd\u0259n art\u0131q qusma,\u00a0 ba\u011f\u0131rsaq obstruksiyas\u0131 v\u0259 s.) v\u0259 y\u00fcks\u0259klik Hb miqdar\u0131nda art\u0131ma s\u0259b\u0259b ola bil\u0259r, anemiya za\u00adman\u0131 v\u0259 uzanm\u0131\u015f v\u0259ziyy\u0259td\u0259 Hb azal\u0131r. Saat 17.00-07.00 aras\u0131nda v\u0259 yem\u0259kd\u0259n sonra Hb miqdar\u0131nda 10% enm\u0259 m\u00fc\u015fahid\u0259 oluna bil\u0259r. H\u0259m\u00ad\u00e7inin qan alark\u0259n turnan\u0131n uzun m\u00fcdd\u0259t qalmas\u0131 yanl\u0131\u015f y\u00fcks\u0259k n\u0259tic\u0259l\u0259r\u0259 s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HBA2 (HEMOQLOB\u0130N A2)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>HbA2<\/sub><\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>2 mL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>HPLC<\/p>\n

><4%<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Talasemiyan\u0131n t\u0259yinind\u0259 istifad\u0259 olunur. HbA2\u00a0<\/sub>miqdar\u0131 d\u0259mir \u00e7at\u0131\u015fmazl\u0131\u011f\u0131n\u0131n t\u0259sirin\u0259 m\u0259ruz qala bil\u0259r. \u0392eta-talasemiya v\u0259 meqa\u00adlo\u00adblas\u00adtik anemiyada HbA2\u00a0<\/sub>s\u0259viyy\u0259si art\u0131r, d\u0259mir \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, eritroley\u00adkemiya, HbH x\u0259st\u0259liyi, \u03b4-talasemiya v\u0259 \u03b2\u03b4-alasemiyada is\u0259 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

BM (METHEMOQLOB\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0MetHb; HbM<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0N\u00fc\u00admu\u00adn\u0259nin laxtal\u0131 v\u0259 ya hemolizli olmas\u0131<\/p>\n

Referens:<\/strong>\u00a0<1.5%<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Anadang\u0259lm\u0259 v\u0259 qaza\u00adn\u0131lm\u0131\u015f methemoqlobinemiya, karbon monooksid z\u0259h\u0259rl\u0259nm\u0259si, benzokain, nitroqliserin, lidokain, nitratlar, fena\u00adsetin, sulfanilamidl\u0259r v\u0259 radiasiya methemoqlobin s\u0259viyy\u0259sinin artma\u00ads\u0131na s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HCT (HEMATOKR\u0130T)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Hct<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>1 mL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>H\u00fcceyr\u0259 say\u0131lmas\u0131 (Cell counter)<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>N\u00fc\u00admun\u0259nin laxtalanm\u0131\u015f olmas\u0131<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259si qan\u0131<\/td>\n42-60%<\/td>\n<\/tr>\n
Erk\u0259n do\u011fulmu\u015f u\u015faqlarda<\/td>\n42-60%<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n45-67%<\/td>\n<\/tr>\n
7 ay-1 ay<\/td>\n42-63%<\/td>\n<\/tr>\n
2-3 ay<\/td>\n31-55%<\/td>\n<\/tr>\n
4-6 ay<\/td>\n29-41%<\/td>\n<\/tr>\n
7 ay-3 ya\u015f<\/td>\n33-39%<\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n34-40%<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n33-45%<\/td>\n<\/tr>\n
<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n37-49%<\/td>\n36-46%<\/td>\n<\/tr>\n
16-50 ya\u015f<\/td>\n40-53%<\/td>\n36-46%<\/td>\n<\/tr>\n
>50 ya\u015f<\/td>\n41-53%<\/td>\n36-46%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Anemiya, qan itkisi, po\u00adlisitemiya v\u0259 s. hallar\u0131n qiym\u0259tl\u0259n\u00addi\u00adrilm\u0259sind\u0259 istifad\u0259 olunur. Polisite\u00admiya, idman, hemokonsentrasiya za\u00adman\u0131 (dehidratasiya, yan\u0131q, h\u0259dd\u0259n art\u0131q qusma, ba\u011f\u0131rsaq obstruksiyas\u0131 v\u0259 s.) v\u0259 y\u00fcks\u0259klikl\u0259rd\u0259\u00a0 Hct art\u0131m\u0131 ba\u015f ver\u0259 bil\u0259r, anemiya v\u0259 uzanm\u0131\u015f v\u0259ziyy\u0259td\u0259 Hct azal\u0131r. Saat 17.00-07.00 aras\u0131nda v\u0259 yem\u0259kd\u0259n sonra Hct-nin s\u0259viyy\u0259sind\u0259 10% enm\u0259 m\u00fc\u00ad\u015fahid\u0259 oluna bil\u0259r. H\u0259m\u00e7inin qan alar\u00adk\u0259n turnan\u0131n uzun m\u00fcdd\u0259t qal\u00admas\u0131 yanl\u0131\u015f y\u00fcks\u0259k n\u0259tic\u0259l\u0259r\u0259 s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HEMATOKR\u0130T<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Hct<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>1 mL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>H\u00fcceyr\u0259 say\u0131lmas\u0131 (Cell counter)<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>N\u00fc\u00admun\u0259nin laxtalanm\u0131\u015f olmas\u0131<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259si qan\u0131<\/td>\n42-60%<\/td>\n<\/tr>\n
Erk\u0259n do\u011fulmu\u015f u\u015faqlarda<\/td>\n42-60%<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n45-67%<\/td>\n<\/tr>\n
7 ay-1 ay<\/td>\n42-63%<\/td>\n<\/tr>\n
2-3 ay<\/td>\n31-55%<\/td>\n<\/tr>\n
4-6 ay<\/td>\n29-41%<\/td>\n<\/tr>\n
7 ay-3 ya\u015f<\/td>\n33-39%<\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n34-40%<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n33-45%<\/td>\n<\/tr>\n
<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n37-49%<\/td>\n36-46%<\/td>\n<\/tr>\n
16-50 ya\u015f<\/td>\n40-53%<\/td>\n36-46%<\/td>\n<\/tr>\n
>50 ya\u015f<\/td>\n41-53%<\/td>\n36-46%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Anemiya, qan itkisi, po\u00adlisitemiya v\u0259 s. hallar\u0131n qiym\u0259tl\u0259n\u00addi\u00adrilm\u0259sind\u0259 istifad\u0259 olunur. Polisite\u00admiya, idman, hemokonsentrasiya za\u00adman\u0131 (dehidratasiya, yan\u0131q, h\u0259dd\u0259n art\u0131q qusma, ba\u011f\u0131rsaq obstruksiyas\u0131 v\u0259 s.) v\u0259 y\u00fcks\u0259klikl\u0259rd\u0259\u00a0 Hct art\u0131m\u0131 ba\u015f ver\u0259 bil\u0259r, anemiya v\u0259 uzanm\u0131\u015f v\u0259ziyy\u0259td\u0259 Hct azal\u0131r. Saat 17.00-07.00 aras\u0131nda v\u0259 yem\u0259kd\u0259n sonra Hct-nin s\u0259viyy\u0259sind\u0259 10% enm\u0259 m\u00fc\u00ad\u015fahid\u0259 oluna bil\u0259r. H\u0259m\u00e7inin qan alar\u00adk\u0259n turnan\u0131n uzun m\u00fcdd\u0259t qal\u00admas\u0131 yanl\u0131\u015f y\u00fcks\u0259k n\u0259tic\u0259l\u0259r\u0259 s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HEMATOLOJ\u0130 KONSULTAS\u0130YA<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Periferik qandan preparat v\u0259 klinik m\u0259lumat<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Mikroskopik<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HEMOQLOB\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Hb<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>1 mL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>H\u00fcceyr\u0259 say\u0131lmas\u0131 (Cell counter)<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0N\u00fc\u00admun\u0259nin laxtalanm\u0131\u015f olmas\u0131<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259si qan\u0131<\/td>\n13.5-20.0 g\/dL<\/td>\n<\/tr>\n
Erk\u0259n do\u011fulmu\u015f u\u015faqlarda<\/td>\n13.5-20.0 g\/dL<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n14.5-22.5 g\/dL<\/td>\n<\/tr>\n
7 g\u00fcn-1 ay<\/td>\n13.5-20.5 g\/dL<\/td>\n<\/tr>\n
<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
2-3 ay<\/td>\n10.0-14.5 g\/dL<\/td>\n10.0-14.0 g\/dL<\/td>\n<\/tr>\n
4-6 ay<\/td>\n9.5-13.5 g\/dL<\/td>\n9.5-13.5 g\/dL<\/td>\n<\/tr>\n
7 ay-3 ya\u015f<\/td>\n10.5-13.5 g\/dL<\/td>\n10.5-13.5 g\/dL<\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n11.5-13.5 g\/dL<\/td>\n11.5-13.5 g\/dL<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n11.5-15.5 g\/dL<\/td>\n11.5-15.5 g\/dL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n13.0-16.0 g\/dL<\/td>\n12.0-16.0 g\/dL<\/td>\n<\/tr>\n
16-50 ya\u015f<\/td>\n13.5-17.5 g\/dL<\/td>\n12.0-16.0 g\/dL<\/td>\n<\/tr>\n
>50 ya\u015f<\/td>\n14.0-18.0 g\/dL<\/td>\n13.0-17.0 g\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Anemiya, qan itkisi, po\u00adlistemiya v\u0259 dig\u0259r v\u0259ziyy\u0259tl\u0259rin qiy\u00adm\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olunur. Polistemiya, idman, hemokon\u00adsentra\u00adsiya (dehidratasiya, yan\u0131q, h\u0259dd\u0259n art\u0131q qusma,\u00a0 ba\u011f\u0131rsaq obstruksiyas\u0131 v\u0259 s.) v\u0259 y\u00fcks\u0259klik Hb miqdar\u0131nda art\u0131ma s\u0259b\u0259b ola bil\u0259r, anemiya za\u00adman\u0131 v\u0259 uzanm\u0131\u015f v\u0259ziyy\u0259td\u0259 Hb azal\u0131r. Saat 17.00-07.00 aras\u0131nda v\u0259 yem\u0259kd\u0259n sonra Hb miqdar\u0131nda 10% enm\u0259 m\u00fc\u015fahid\u0259 oluna bil\u0259r. H\u0259m\u00ad\u00e7inin qan alark\u0259n turnan\u0131n uzun m\u00fcdd\u0259t qalmas\u0131 yanl\u0131\u015f y\u00fcks\u0259k n\u0259tic\u0259l\u0259r\u0259 s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HEMOQLOB\u0130N A2<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>HbA2<\/sub><\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a02 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0HPLC<\/p>\n

Referens:\u00a0<\/strong><4%<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Talasemiyan\u0131n t\u0259yinind\u0259 istifad\u0259 olunur. HbA2\u00a0<\/sub>miqdar\u0131 d\u0259mir \u00e7at\u0131\u015fmazl\u0131\u011f\u0131n\u0131n t\u0259sirin\u0259 m\u0259ruz qala bil\u0259r. \u0392eta-talasemiya v\u0259 meqa\u00adlo\u00adblas\u00adtik anemiyada HbA2\u00a0<\/sub>s\u0259viyy\u0259si art\u0131r, d\u0259mir \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, eritroley\u00adkemiya, HbH x\u0259st\u0259liyi, \u03b4-talasemiya v\u0259 \u03b2\u03b4-alasemiyada is\u0259 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HEMOQLOB\u0130N ELEKTROFOREZ\u0130<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Hb elektroforezi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a02mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0\u03b2-talasemiya v\u0259 hemo\u00adqlobinopatiyalar \u00fc\u00e7\u00fcn birinci add\u0131m skrininq test kimi elektroforez \u00fcsulu n\u0259 q\u0259d\u0259r geni\u015f istifad\u0259si\u00a0 olunsa da,\u00a0 HPLC \u00fcsulu il\u0259 apar\u0131lan analizl\u0259rin h\u0259m h\u0259ssasl\u0131\u011f\u0131, h\u0259m d\u0259 d\u0259qiqliyi \u00e7ox y\u00fcks\u0259k oldu\u011fundan bu \u00fcsul t\u00f6vsiy\u0259 olunur. X\u00fcsusi ist\u0259kd\u0259n as\u0131l\u0131 olaraq v\u0259 ya HPLC il\u0259 \u0259ld\u0259 olunan n\u0259tic\u0259\u00adl\u0259rin d\u0259qiql\u0259\u015fdirilm\u0259si m\u0259qs\u0259di il\u0259 laz\u0131m g\u0259ldikd\u0259 aqaroza gel \u00fcsulu da istifad\u0259 olunur<\/p>\n

Referens:\u00a0<\/strong>\u00a0% -l\u0259:<\/p>\n\n\n\n\n\n\n\n\n\n
<\/td>\nHbA2<\/sub><\/td>\nHbF<\/td>\nHbS<\/td>\nHbA<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n<4.0<\/td>\n69.0-85.0<\/td>\n<1.5<\/td>\n15.0-30.0<\/td>\n<\/tr>\n
1 H\u0259ft\u0259- 1ay<\/td>\n<4.0<\/td>\n69-0-85.0<\/td>\n<1.5<\/td>\n20.0-40.0<\/td>\n<\/tr>\n
2- 6 ay<\/td>\n<4.0<\/td>\n69.0-85.0<\/td>\n<1.5<\/td>\n25.0-95.0<\/td>\n<\/tr>\n
7 ay-1 ya\u015f<\/td>\n<4.0<\/td>\n69.0-85.0<\/td>\n<1.5<\/td>\n87.0-98.0<\/td>\n<\/tr>\n
2-3 ya\u015f<\/td>\n<4.0<\/td>\n2.0<\/td>\n<1.5<\/td>\n94.0-98.0<\/td>\n<\/tr>\n
>3 ya\u015f<\/td>\n<4.0<\/td>\n2.0<\/td>\n<1.5<\/td>\n94.0-99.0<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Talasemiya v\u0259 dig\u0259r he\u00admo\u00adqlobin variasiyalar\u0131n\u0131n t\u0259yinind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HEMOQRAM (TAM QAN SAYILMASI)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Complete blood count; CBC; Hemoqram, qanin \u00fcmumi analizi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Cell counter (h\u00fcceyr\u0259 say\u0131lmas\u0131)<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0N\u00fc\u00admun\u0259nin laxtal\u0131 olmas\u0131<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Hematoloji x\u0259st\u0259likl\u0259r, k\u0259s\u00adkin v\u0259 xroniki infeksiyalar, \u0259m\u0259\u00adliy\u00adyatdan \u0259vv\u0259l v\u0259 s. hallarda istifad\u0259 olunur. X\u0259st\u0259nin \u00fcmumi sa\u011flaml\u0131q v\u0259ziyy\u0259ti haqq\u0131nda m\u0259lumat verir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HEPAR\u0130N KOFAKTOR ANAL\u0130Z\u0130 (ANT\u0130TROMB\u0130N III)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>AT III; Heparin kofaktor \u00e7al\u0131\u015fmas\u0131<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>200 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admu\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admo\u00adliz\u0259 u\u011framadan d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>Uy\u00ad\u011fun olmayan qan\/antikoaqulyant nis\u00adb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fc\u00admun\u0259l\u0259r<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
< 3 ay<\/td>\n35-125%<\/td>\n<\/tr>\n
>3ay<\/td>\n70-125%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>AT III \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 hi\u00adper\u00adkoaquliyasiyaya s\u0259b\u0259b olan faktor\u00adlar\u00addan biridir. AT III azl\u0131\u011f\u0131 genetik (auto\u00adsom dominant) v\u0259 ya qaza\u00adn\u0131lm\u0131\u015f s\u0259\u00adb\u0259bl\u0259rl\u0259 \u0259laq\u0259dar ola bil\u0259r. A\u011f\u0131r sirroz, DIC, a\u011fciy\u0259r emboliyas\u0131 v\u0259 c\u0259rrahi \u0259m\u0259liyatlar qazan\u0131lm\u0131\u015f s\u0259b\u0259bl\u0259rd\u0259ndir. F\u0259rdi v\u0259 ya irsi trombemboliya x\u0259s\u00adt\u0259\u00adliyi olanlarda v\u0259 yet\u0259rsiz heparin m\u00fca\u00adli\u00adc\u0259si zaman\u0131\u00a0 AT III s\u0259viyy\u0259si t\u0259yin olunmal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

KR\u0130OF\u0130BR\u0130NOGEN<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 plazma (qan al\u0131nd\u0131qdan sonra 37o<\/sup>C su hama\u00adm\u0131nda bir m\u00fcdd\u0259t saxlan\u0131lmal\u0131, daha sonra is\u0259 sentrifuqadan ke\u00e7iri\u00adl\u0259r\u0259k plazmas\u0131 ayr\u0131lmal\u0131d\u0131r)<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a02.5 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Presipitasiya<\/p>\n

Referens:<\/strong>\u00a0Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Qanda kryoqlobulin s\u0259\u00adviy\u00ady\u0259sinin y\u00fcks\u0259k oldu\u011fu hallar, hemofiliya, k\u0259skin FMF krizi v\u0259 oral kontraseptiv istifad\u0259 ed\u0259nl\u0259rd\u0259 kriofib\u00adrinogenin s\u0259viyy\u0259si y\u00fcks\u0259k ola bil\u0259r. Heparin istifad\u0259si yalan\u00e7\u0131 neqativ n\u0259tic\u0259l\u0259r\u0259 s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

KR\u0130OQLOBUL\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum (qan al\u0131n\u00add\u0131q\u00addan sonra koaqulyasiya tamam\u00adla\u00adna\u00adna q\u0259d\u0259r 37o<\/sup>C su hamam\u0131nda bir m\u00fcdd\u0259t saxlan\u0131lmal\u0131, daha sonra is\u0259 sentrafuqadan ke\u00e7iril\u0259r\u0259k plazmas\u0131 ayr\u0131lmal\u0131d\u0131r)<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a02.5 mL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a04-6 saat ac\u00adl\u0131qdan sonra n\u00fcmun\u0259 al\u0131nmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Presipitasiya<\/p>\n

Referens:<\/strong>\u00a0Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Reynaud b\u0259nz\u0259r simp\u00adto\u00admu olan x\u0259st\u0259l\u0259rd\u0259 krioqlobuli\u00adne\u00admi\u00adyan\u0131n diaqnozunda istifad\u0259 olunur. Neoplastik x\u0259st\u0259likl\u0259r, k\u0259skin v\u0259 xro\u00adniki infeksiyalar v\u0259 kollagen to\u00adxu\u00adma x\u0259st\u0259\u0131likl\u0259rind\u0259 serumda krioqlobulinin s\u0259viyy\u0259si art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

LA-DVV (LUPUS ANT\u0130KOAQULYANT SKR\u0130N\u0130NQ)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0PTT-LA; LA-DVV; dRVVT testi; Dilite Russell viper venom time<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259ril\u00adm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan qan \/ antikoaqulyant miqdar\u0131, laxtal\u0131, hemolizli heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:<\/strong>\u00a0Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Lupus anticisiml\u0259ri, SLE, trombotik hallar, t\u0259krarlanan d\u00f6l it\u00adkil\u0259ri, trombositopeniya v\u0259 m\u00fcxt\u0259lif nevroloji poz\u011funluqlarla \u0259laq\u0259lidir. Dig\u0259r autoimmun poz\u011funluqlar, b\u0259d\u00adxass\u0259li t\u00f6r\u0259m\u0259l\u0259r, infeksiyalar v\u0259 b\u0259\u00adzi d\u0259rmanlar\u0131n istifad\u0259sind\u0259 d\u0259 (m\u0259s. fenotiazinl\u0259r v\u0259 \u00fcr\u0259k antiaritmik preparatlar\u0131) lupus antikoaqulyantlar\u0131 tap\u0131la bil\u0259r. Bu x\u0259st\u0259l\u0259rd\u0259 aPTT kimi fosfolipid as\u0131l\u0131 in vitro laxtalanma testl\u0259rind\u0259 uzanma ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

LAB\u0130L FAKTOR (FAKTOR V)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>AC globulin; Labil faktor; Plazma akselerator globulin; Pro\u00adakselerin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan qan\/antikoaqulyant nis\u00adb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fc\u00admun\u0259l\u0259r<\/p>\n

Referens:<\/strong>\u00a0Normal aktivliyin\u00a0 50-150 %-i<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>V faktorun\u00a0 irsi \u00e7at\u0131\u00ad\u015f\u00admaz\u00adl\u0131\u011f\u0131 olan x\u0259st\u0259l\u0259rd\u0259 (parahe\u00admofiliya) anormal qanaxmalar m\u00fc\u015fahid\u0259 olu\u00adnur v\u0259 laxtalanma zaman\u0131, PT v\u0259 APTT testl\u0259rind\u0259 uzanmalar m\u00fc\u0259y\u00ady\u0259n edilir. Hamil\u0259lik zaman\u0131 bir s\u0131ra laxtalanma faktorlar\u0131 kimi V faktor\u00adda da az miqdarda art\u0131m ba\u015f ver\u0259 bil\u0259r. K\u0259skin qaraciy\u0259r \u00e7at\u0131\u015fmazl\u0131\u00ad\u011f\u0131nda sintezin z\u0259ifl\u0259m\u0259si, DDL za\u00adman\u0131 is\u0259 s\u0259rf olunman\u0131n artmas\u0131 il\u0259 \u0259laq\u0259dar olaraq V faktorun miqdar\u0131 azal\u0131r. V faktorun t\u0259yini qaraciy\u0259r x\u0259st\u0259liyi v\u0259 K vitamini \u00e7at\u0131\u015fmaz\u00adl\u0131\u011f\u0131n\u0131n differensiasiyas\u0131nda istifad\u0259 olunur. Parenximal qaraciy\u0259r x\u0259st\u0259\u00adlik\u00adl\u0259rind\u0259 V faktor v\u0259 K vita\u00admi\u00adnin\u00add\u0259n as\u0131l\u0131 sintez olunan laxtalanma faktorlar\u0131 (II, VII, IX v\u0259 X faktorlar) azald\u0131\u011f\u0131 halda, K vitamini \u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u011f\u0131nda V faktor normal, dig\u0259r fak\u00adtorlar\u0131n miqdar\u0131 is\u0259 a\u015fa\u011f\u0131 olur. Bu m\u0259q\u00ads\u0259dl\u0259 V v\u0259 VII faktorlar\u0131n aktiv\u00adliyi t\u0259yin oluna bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

LAP (LEYKOS\u0130T Q\u018fL\u018fV\u0130 FOSFATAZA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0LAP; LAP skoru; LAPA; Neytrofil q\u0259l\u0259vi fosfataza<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Heparinli v\u0259 ya adi qandan t\u0259z\u0259 haz\u0131rlanm\u0131\u015f 8-10 \u0259d\u0259d preparat (yaxma). (barmaq ucundan hazirlanan yaxmalar da istifad\u0259 oluna bil\u0259r)<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0X\u00fcsusi boyama + mikro\u00adskopik m\u00fcayin\u0259<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan s\u0131naq \u015f\u00fc\u015f\u0259si v\u0259 ya uzun m\u00fcdd\u0259t saxlan\u0131lm\u0131\u015f qandan haz\u0131r\u00adlanan yaxmalar<\/p>\n

Referens:<\/strong>\u00a030-140 %<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Xroniki mieloid leykoz il\u0259 leykomoid reaksiyas\u0131 v\u0259 polisi\u00adtemia vera il\u0259 ikincili polisite\u00admi\u00adya\u00adn\u0131n differensasiyas\u0131nda istifad\u0259 olu\u00adnur. Polisitemia vera, leykomoid reaksiyalar, Daun sindromu, mielo\u00adproliferativ x\u0259st\u0259likl\u0259r, stress, hami\u00adl\u0259\u00adlik, k\u0259skin limfositar leykoz, Hodgkin limfomas\u0131, aplastik ane\u00admiya v\u0259 bakterial infeksiyalarda LAP y\u00fcks\u0259lir, xroniki mieloid ley\u00adkoz, sideroblastik anemiya, \u0130TP (\u0130m\u00admun Trombositopenik Purpura), PHN (Paroksizmal Nokturnal Hemo\u00adqlobinuriya), kollagen toxuma x\u0259st\u0259\u00adlikl\u0259ri, k\u0259skin mielositar leykoz, sir\u00adroz, k\u0259skin \u00fcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, \u015f\u0259k\u0259rli diabet, podaqra, pernisitoz anemiya v\u0259 sarkoidozda is\u0259 LAP azal\u0131r. H\u0259m\u00ad\u00e7inin xroniki mieloid leykozun re\u00admis\u00adsiya d\u00f6vr\u00fcnd\u0259 LAP normalla\u015fa bi\u00adl\u0259r. Blast krizi v\u0259 ya aqressiv fazada is\u0259 LAP arta bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

LAP SKORU (LEYKOS\u0130T Q\u018fL\u018fV\u0130 FOSFATAZA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0LAP; LAP skoru; LAPA; Neytrofil q\u0259l\u0259vi fosfataza<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Heparinli v\u0259 ya adi qandan t\u0259z\u0259 haz\u0131rlanm\u0131\u015f 8-10 \u0259d\u0259d preparat (yaxma). (barmaq ucundan hazirlanan yaxmalar da istifad\u0259 oluna bil\u0259r)<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0X\u00fcsusi boyama + mikro\u00adskopik m\u00fcayin\u0259<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan s\u0131naq \u015f\u00fc\u015f\u0259si v\u0259 ya uzun m\u00fcdd\u0259t saxlan\u0131lm\u0131\u015f qandan haz\u0131r\u00adlanan yaxmalar<\/p>\n

Referens:<\/strong>\u00a030-140 %<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Xroniki mieloid leykoz il\u0259 leykomoid reaksiyas\u0131 v\u0259 polisi\u00adtemia vera il\u0259 ikincili polisite\u00admi\u00adya\u00adn\u0131n differensasiyas\u0131nda istifad\u0259 olu\u00adnur. Polisitemia vera, leykomoid reaksiyalar, Daun sindromu, mielo\u00adproliferativ x\u0259st\u0259likl\u0259r, stress, hami\u00adl\u0259\u00adlik, k\u0259skin limfositar leykoz, Hodgkin limfomas\u0131, aplastik ane\u00admiya v\u0259 bakterial infeksiyalarda LAP y\u00fcks\u0259lir, xroniki mieloid ley\u00adkoz, sideroblastik anemiya, \u0130TP (\u0130m\u00admun Trombositopenik Purpura), PHN (Paroksizmal Nokturnal Hemo\u00adqlobinuriya), kollagen toxuma x\u0259st\u0259\u00adlikl\u0259ri, k\u0259skin mielositar leykoz, sir\u00adroz, k\u0259skin \u00fcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, \u015f\u0259k\u0259rli diabet, podaqra, pernisitoz anemiya v\u0259 sarkoidozda is\u0259 LAP azal\u0131r. H\u0259m\u00ad\u00e7inin xroniki mieloid leykozun re\u00admis\u00adsiya d\u00f6vr\u00fcnd\u0259 LAP normalla\u015fa bi\u00adl\u0259r. Blast krizi v\u0259 ya aqressiv fazada is\u0259 LAP arta bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

LAXTALANMA ZAMANI<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a02mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131<\/strong>:<\/strong>\u00a0Testin h\u0259yata ke\u00e7irilm\u0259si \u00fc\u00e7\u00fcn x\u0259st\u0259 labo\u00adratoriyaya g\u0259lm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0S\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0La\u00adbo\u00adratoriyadan k\u0259nada al\u0131nan n\u00fcmu\u00adn\u0259l\u0259r q\u0259bul edilmir<\/p>\n

Referens<: <<\/strong>15 d\u0259qiq\u0259<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Qanaxma poz\u011fun\u00adluq\u00adla\u00adr\u0131\u00adna s\u0259b\u0259b olan x\u0259st\u0259likl\u0259rin qiym\u0259t\u00adl\u0259n\u00addirilm\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

LE H\u00dcCEYR\u018fS\u0130<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Lupus erythematosus h\u00fc\u00adceyr\u0259 testi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>D\u00fcz qan (serumu ayr\u0131lmadan v\u0259 otaq temperaturunda g\u00f6nd\u0259rilm\u0259lidir), maye<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (d\u00fcz qan), gelsiz d\u00fcz s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (maye)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>10 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Mikroskopik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0N\u00fc\u00admun\u0259nin uy\u011fun olmayan s\u0131naq \u015f\u00fc\u00ad\u015f\u0259sind\u0259 al\u0131nmas\u0131, sentrifuqadan ke\u00e7i\u00adrilm\u0259si, miqdar\u0131n\u0131n az olmas\u0131 v\u0259 hemolizli olmas\u0131<\/p>\n

Referens:<\/strong>\u00a0Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0SLE-li x\u0259st\u0259l\u0259rin 70-90 %-d\u0259 LE h\u00fcceyr\u0259si tap\u0131l\u0131r. H\u0259m\u00e7inin rev\u00admatoid artrid, sklerodermiya, bir\u00adl\u0259\u015f\u00addirici toxuma x\u0259st\u0259likl\u0259ri, d\u0259rman reaksiyalar\u0131 v\u0259 lupoid hepatitd\u0259 d\u0259 LE h\u00fcceyr\u0259si 3-9 % nisb\u0259tind\u0259 ta\u00adp\u0131l\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

LEYKOS\u0130T<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0A\u011f qan h\u00fcceyr\u0259l\u0259rinin say\u0131; WBC<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>1mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0H\u00fcceyr\u0259 say\u0131m\u0131<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n
Yenido\u011fulmu\u015f<\/td>\n9.0-30.0 K\/mm3<\/sup><\/td>\n<\/tr>\n
<1 ay<\/td>\n9.4-34.0 K\/mm3<\/sup><\/td>\n<\/tr>\n
2-12 ay<\/td>\n5.0-19.5 K\/mm3<\/sup><\/td>\n<\/tr>\n
1-3 ya\u015f<\/td>\n6.0-17.5 K\/mm3<\/sup><\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n5.5-15.5 K\/mm3<\/sup><\/td>\n<\/tr>\n
6-15 ya\u015f<\/td>\n4.5-13.5 K\/mm3<\/sup><\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n4.5-11.0 K\/mm3<\/sup><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Qandak\u0131 a\u011f qan h\u00fcceyr\u0259\u00adl\u0259rinin say\u0131n\u0131n qiym\u0259tl\u0259n\u00addiril\u00adm\u0259\u00adsin\u00add\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

LEYKOS\u0130T (BOM)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>500 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Mikroskopik<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>MSS-nin x\u0259st\u0259likl\u0259rinin differensasiyas\u0131nda istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

LEYKOS\u0130T Q\u018fL\u018fV\u0130 FOSFATAZA<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0LAP; LAP skoru; LAPA; Neytrofil q\u0259l\u0259vi fosfataza<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Heparinli v\u0259 ya adi qandan t\u0259z\u0259 haz\u0131rlanm\u0131\u015f 8-10 \u0259d\u0259d preparat (yaxma). (barmaq ucundan hazirlanan yaxmalar da istifad\u0259 oluna bil\u0259r)<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0X\u00fcsusi boyama + mikro\u00adskopik m\u00fcayin\u0259<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan s\u0131naq \u015f\u00fc\u015f\u0259si v\u0259 ya uzun m\u00fcdd\u0259t saxlan\u0131lm\u0131\u015f qandan haz\u0131r\u00adlanan yaxmalar<\/p>\n

Referens:<\/strong>\u00a030-140 %<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Xroniki mieloid leykoz il\u0259 leykomoid reaksiyas\u0131 v\u0259 polisi\u00adtemia vera il\u0259 ikincili polisite\u00admi\u00adya\u00adn\u0131n differensasiyas\u0131nda istifad\u0259 olu\u00adnur. Polisitemia vera, leykomoid reaksiyalar, Daun sindromu, mielo\u00adproliferativ x\u0259st\u0259likl\u0259r, stress, hami\u00adl\u0259\u00adlik, k\u0259skin limfositar leykoz, Hodgkin limfomas\u0131, aplastik ane\u00admiya v\u0259 bakterial infeksiyalarda LAP y\u00fcks\u0259lir, xroniki mieloid ley\u00adkoz, sideroblastik anemiya, \u0130TP (\u0130m\u00admun Trombositopenik Purpura), PHN (Paroksizmal Nokturnal Hemo\u00adqlobinuriya), kollagen toxuma x\u0259st\u0259\u00adlikl\u0259ri, k\u0259skin mielositar leykoz, sir\u00adroz, k\u0259skin \u00fcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, \u015f\u0259k\u0259rli diabet, podaqra, pernisitoz anemiya v\u0259 sarkoidozda is\u0259 LAP azal\u0131r. H\u0259m\u00ad\u00e7inin xroniki mieloid leykozun re\u00admis\u00adsiya d\u00f6vr\u00fcnd\u0259 LAP normalla\u015fa bi\u00adl\u0259r. Blast krizi v\u0259 ya aqressiv fazada is\u0259 LAP arta bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

LEYKOZ PANEL\u0130 (\u0130MMUNFENOT\u0130PL\u018fND\u0130RM\u018f PANEL\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Leykemiya paneli<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 v\u0259 ya he\u00adpa\u00adrinli tam qan, EDTA-l\u0131 v\u0259 ya he\u00adpa\u00adrinli s\u00fcm\u00fck iliyi, t\u0259z\u0259 limfa d\u00fc\u00ady\u00fcn\u00fc, BOM, bronxoalveolyar lavaj mayesi, t\u0259z\u0259 dalaq toxumas\u0131, k\u00f6k h\u00fcceyr\u0259<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi (EDTA-l\u0131) v\u0259 ya ya\u015f\u0131l (heparinli) qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si, gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si (maye)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0Periferik qan v\u0259 s\u00fcm\u00fck iliyi (5 mL), BOM, bronxo\u00adal\u00adveolyar lavaj mayesi, orqanizm mayel\u0259ri (10 mL)<\/p>\n

Testin t\u0259rkibi:\u00a0<\/strong>Bax\u0131lan monoklo\u00adnal\u00adlar\u0131n \u0259hat\u0259si \u0259lav\u0259 H-da verilmi\u015fdir<\/p>\n

Lazimi m\u0259lumatlar:\u00a0<\/strong>X\u0259st\u0259 haq\u00adq\u0131nda klinik m\u0259lumat, h\u0259kiminin ad\u0131 v\u0259 telefonu bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Flow cytometry<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>Lax\u00adtal\u0131 n\u00fcm\u00fcn\u0259l\u0259r, h\u00fcceyr\u0259 miqdar\u0131 v\u0259 h\u0259yatilik qabiliyy\u0259tinin azl\u0131\u011f\u0131<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Limfomalar\u0131n tipl\u0259n\u00addiril\u00adm\u0259sind\u0259 istifad\u0259 olunur. Standart pa\u00adneld\u0259n ba\u015fqa \u0259lav\u0259 monoklonallar\u0131n t\u0259yini laz\u0131md\u0131rsa bildirilm\u0259lidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

LEYKOZ TRANSLOKAS\u0130YA PANEL\u0130<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0EDTA-l\u0131 v\u0259 ya heparinli tam qan, EDTA-l\u0131 v\u0259 ya heparinli s\u00fcm\u00fck iliyi<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi (EDTA-l\u0131) v\u0259 ya ya\u015f\u0131l (heparinli) qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>5mL<\/p>\n

Test i\u00e7eri\u011fi<\/strong>:<\/strong>\u00a0t(9;22), t(14;18), t(8;21), inverisiya 17<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0N\u00fc\u00admu\u00adn\u0259 al\u0131nd\u0131qdan sonra soyuq \u015f\u0259\u00adraitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259ril\u00adm\u0259\u00adli\u00addir. N\u00fcmun\u0259 48 saat \u0259rzind\u0259 labo\u00adratoriyaya \u00e7atd\u0131r\u0131lmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0RT-PCR<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0N\u00fc\u00admun\u0259nin 48 saatdan uzun m\u00fcdd\u0259t saxlan\u0131lm\u0131\u015f olmas\u0131, soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259m\u0259si<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Leykozlar\u0131n differensial diaqnostikas\u0131nda v\u0259 tipl\u0259ndiril\u00adm\u0259\u00adsin\u00add\u0259 istifad\u0259 olunur. FAB t\u0259snifat\u0131na g\u00f6r\u0259 t(8;21) k\u0259skin mieloid leykoz-M2-d\u0259 tap\u0131l\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

L\u0130MFOMA PANEL\u0130<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 v\u0259 ya hepa\u00adrinli tam qan, EDTA-l\u0131 v\u0259 ya heparinli s\u00fcm\u00fck iliyi<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi (EDTA-l\u0131) v\u0259 ya ya\u015f\u0131l (heparinli) qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0Perifirik qan (5 mL)<\/p>\n

Test t\u0259rkibi:<\/strong>\u00a0\u018flav\u0259 H-da bu bar\u0259d\u0259 m\u0259lumat verilmi\u015fdir<\/p>\n

Laz\u0131mi m\u0259lumatlar:<\/strong>\u00a0X\u0259st\u0259 haq\u00adq\u0131n\u00adda klinik m\u0259lumat, m\u00fcalic\u0259 h\u0259ki\u00adminin ad\u0131 v\u0259 telofonu g\u00f6nd\u0259ril\u00adm\u0259\u00adlidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Flow cytometry<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Lax\u00adta\u00adlanm\u0131\u015f qan n\u00fcmun\u0259l\u0259ri, h\u00fcceyr\u0259 say\u0131n\u0131n v\u0259 h\u0259yatilik qabiliyy\u0259tinin a\u015fa\u011f\u0131 olmas\u0131<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n
CD 3 (T)<\/td>\n60-85 %<\/td>\n<\/tr>\n
CD 19 (B)<\/td>\n7-23 %<\/td>\n<\/tr>\n
CD 4 (Helper)<\/td>\n29-59 %<\/td>\n<\/tr>\n
CD 8 (Supressor)<\/td>\n19-48 %<\/td>\n<\/tr>\n
CD 16-56 (NK)<\/td>\n6-29 %<\/td>\n<\/tr>\n
Aktiv T<\/td>\n7-15 %<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u0130mmun \u00e7at\u0131\u015fmazl\u0131qlar\u0131n, autoimmun, virus m\u0259n\u015f\u0259li v\u0259 xroniki qranulomatoz x\u0259st\u0259likl\u0259rin diaqnoz v\u0259 m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur. \u00dcr\u0259k, qaraciy\u0259r, b\u00f6y\u0259k v\u0259 s\u00fcm\u00fck iliyi transplantasiyalar\u0131n\u0131n m\u00fc\u015fahid\u0259\u00adsind\u0259 d\u0259 faydal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

L\u0130MFOS\u0130T ALT QRUPLARI<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Limfosit tipl\u0259ndirilm\u0259si<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0EDTA-l\u0131 v\u0259 ya he\u00adpa\u00adrinli tam qan, EDTA-l\u0131 v\u0259 ya he\u00adparinli s\u00fcm\u00fck iliyi, bronxoalveolyar lavaj mayesi (BAL)<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi (EDTA-l\u0131) v\u0259 ya ya\u015f\u0131l (heparinli) qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0Periferik qan (5 mL), BAL (10 mL)<\/p>\n

Test t\u0259rkibi:<\/strong>\u00a0\u018flav\u0259 H-da bu bar\u0259d\u0259 m\u0259lumat verilmi\u015fdir<\/p>\n

Lazimi m\u0259lumatlar:\u00a0<\/strong>X\u0259st\u0259 haq\u00adq\u0131nda klinik m\u0259lumat, h\u0259kiminin ad\u0131 v\u0259 telefonu g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Flow cytometry<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Laxtalanm\u0131\u015f qan n\u00fcmun\u0259l\u0259ri, h\u00fccey\u00adr\u0259 say\u0131n\u0131n v\u0259 h\u0259yatilik qabiliyy\u0259tinin a\u015fa\u011f\u0131 olmas\u0131<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u0130mmun \u00e7at\u0131\u015fmazl\u0131qlar\u0131n, autoimmun, virus m\u0259n\u015f\u0259li v\u0259 xroniki qranulomatoz x\u0259st\u0259likl\u0259rin diaqnoz v\u0259 m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur. \u00dcr\u0259k, qaraciy\u0259r, b\u00f6y\u0259k v\u0259 s\u00fcm\u00fck iliyi transplantasiyalar\u0131n\u0131n m\u00fc\u015fahi\u00add\u0259sind\u0259 d\u0259 faydal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

L\u0130MFOS\u0130T T\u0130PL\u018fND\u0130R\u0130LM\u018fS\u0130 (L\u0130MFOMA PANEL\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 v\u0259 ya hepa\u00adrinli tam qan, EDTA-l\u0131 v\u0259 ya heparinli s\u00fcm\u00fck iliyi<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi (EDTA-l\u0131) v\u0259 ya ya\u015f\u0131l (heparinli) qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0Perifirik qan (5 mL)<\/p>\n

Test t\u0259rkibi:<\/strong>\u00a0\u018flav\u0259 H-da bu bar\u0259d\u0259 m\u0259lumat verilmi\u015fdir<\/p>\n

Laz\u0131mi m\u0259lumatlar:<\/strong>\u00a0X\u0259st\u0259 haq\u00adq\u0131n\u00adda klinik m\u0259lumat, m\u00fcalic\u0259 h\u0259ki\u00adminin ad\u0131 v\u0259 telofonu g\u00f6nd\u0259ril\u00adm\u0259\u00adlidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Flow cytometry<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Lax\u00adta\u00adlanm\u0131\u015f qan n\u00fcmun\u0259l\u0259ri, h\u00fcceyr\u0259 say\u0131n\u0131n v\u0259 h\u0259yatilik qabiliyy\u0259tinin a\u015fa\u011f\u0131 olmas\u0131<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n
CD 3 (T)<\/td>\n60-85 %<\/td>\n<\/tr>\n
CD 19 (B)<\/td>\n7-23 %<\/td>\n<\/tr>\n
CD 4 (Helper)<\/td>\n29-59 %<\/td>\n<\/tr>\n
CD 8 (Supressor)<\/td>\n19-48 %<\/td>\n<\/tr>\n
CD 16-56 (NK)<\/td>\n6-29 %<\/td>\n<\/tr>\n
Aktiv T<\/td>\n7-15 %<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u0130mmun \u00e7at\u0131\u015fmazl\u0131qlar\u0131n, autoimmun, virus m\u0259n\u015f\u0259li v\u0259 xroniki qranulomatoz x\u0259st\u0259likl\u0259rin diaqnoz v\u0259 m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur. \u00dcr\u0259k, qaraciy\u0259r, b\u00f6y\u0259k v\u0259 s\u00fcm\u00fck iliyi transplantasiyalar\u0131n\u0131n m\u00fc\u015fahid\u0259\u00adsind\u0259 d\u0259 faydal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

LUPUS ANT\u0130KOAQULYANT SKR\u0130N\u0130NQ<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0PTT-LA; LA-DVV; dRVVT testi; Dilite Russell viper venom time<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259ril\u00adm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan qan \/ antikoaqulyant miqdar\u0131, laxtal\u0131, hemolizli heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:<\/strong>\u00a0Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Lupus anticisiml\u0259ri, SLE, trombotik hallar, t\u0259krarlanan d\u00f6l it\u00adkil\u0259ri, trombositopeniya v\u0259 m\u00fcxt\u0259lif nevroloji poz\u011funluqlarla \u0259laq\u0259lidir. Dig\u0259r autoimmun poz\u011funluqlar, b\u0259d\u00adxass\u0259li t\u00f6r\u0259m\u0259l\u0259r, infeksiyalar v\u0259 b\u0259\u00adzi d\u0259rmanlar\u0131n istifad\u0259sind\u0259 d\u0259 (m\u0259s. fenotiazinl\u0259r v\u0259 \u00fcr\u0259k antiaritmik preparatlar\u0131) lupus antikoaqulyantlar\u0131 tap\u0131la bil\u0259r. Bu x\u0259st\u0259l\u0259rd\u0259 aPTT kimi fosfolipid as\u0131l\u0131 in vitro laxtalanma testl\u0259rind\u0259 uzanma ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

LUPUS ANT\u0130KOAQULYANT T\u018fSD\u0130QL\u018fM\u018f<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Hegzagonal fosfolipid neytralizasiya testi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>250 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259ril\u00adm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>Uy\u00ad\u011fun olmayan qan \/ antikoaqulyant miqdar\u0131, laxtal\u0131, hemolizli, heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:<\/strong>\u00a0Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Lupus anticisiml\u0259rinin varl\u0131\u011f\u0131n\u0131n t\u0259sdiqind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

NEYTROF\u0130L Q\u018fL\u018fV\u0130 FOSFATAZA (LEYKOS\u0130T Q\u018fL\u018fV\u0130 FOSFATAZA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0LAP; LAP skoru; LAPA; Neytrofil q\u0259l\u0259vi fosfataza<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Heparinli v\u0259 ya adi qandan t\u0259z\u0259 haz\u0131rlanm\u0131\u015f 8-10 \u0259d\u0259d preparat (yaxma). (barmaq ucundan hazirlanan yaxmalar da istifad\u0259 oluna bil\u0259r)<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0X\u00fcsusi boyama + mikro\u00adskopik m\u00fcayin\u0259<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan s\u0131naq \u015f\u00fc\u015f\u0259si v\u0259 ya uzun m\u00fcdd\u0259t saxlan\u0131lm\u0131\u015f qandan haz\u0131r\u00adlanan yaxmalar<\/p>\n

Referens:<\/strong>\u00a030-140 %<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Xroniki mieloid leykoz il\u0259 leykomoid reaksiyas\u0131 v\u0259 polisi\u00adtemia vera il\u0259 ikincili polisite\u00admi\u00adya\u00adn\u0131n differensasiyas\u0131nda istifad\u0259 olu\u00adnur. Polisitemia vera, leykomoid reaksiyalar, Daun sindromu, mielo\u00adproliferativ x\u0259st\u0259likl\u0259r, stress, hami\u00adl\u0259\u00adlik, k\u0259skin limfositar leykoz, Hodgkin limfomas\u0131, aplastik ane\u00admiya v\u0259 bakterial infeksiyalarda LAP y\u00fcks\u0259lir, xroniki mieloid ley\u00adkoz, sideroblastik anemiya, \u0130TP (\u0130m\u00admun Trombositopenik Purpura), PHN (Paroksizmal Nokturnal Hemo\u00adqlobinuriya), kollagen toxuma x\u0259st\u0259\u00adlikl\u0259ri, k\u0259skin mielositar leykoz, sir\u00adroz, k\u0259skin \u00fcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, \u015f\u0259k\u0259rli diabet, podaqra, pernisitoz anemiya v\u0259 sarkoidozda is\u0259 LAP azal\u0131r. H\u0259m\u00ad\u00e7inin xroniki mieloid leykozun re\u00admis\u00adsiya d\u00f6vr\u00fcnd\u0259 LAP normalla\u015fa bi\u00adl\u0259r. Blast krizi v\u0259 ya aqressiv fazada is\u0259 LAP arta bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ORAQLA\u015eMA TEST\u0130 (S\u0130KL\u0130NG TEST\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Oraqla\u015fma testi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>1mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0\u00c7\u00f6z\u00fcn\u00fcrl\u00fck<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0N\u00fc\u00admun\u0259nin laxtal\u0131 v\u0259 ya hemolizli olmas\u0131<\/p>\n

Referens:<\/strong>\u00a0Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Oraq h\u00fcceyr\u0259li ane\u00admi\u00adyan\u0131n t\u0259yinind\u0259 istifad\u0259 ounur. HbS (> 25% oldu\u011fu hallar) v\u0259 dig\u0259r oraq\u00adla\u015fmaya s\u0259b\u0259b olan hemo\u00adqlo\u00adbinl\u0259r (m\u0259s. HbC-Harlen) m\u00f6vcud olduqda test pozitiv olur. Oraq h\u00fcceyr\u0259li ane\u00admiya, sickle trait (oraq xarakterli) v\u0259 HbS-in dig\u0259r x\u0259st\u0259likl\u0259rl\u0259 kombi\u00adna\u00adsiya oldu\u011fu hallarda (betta-tala\u00adse\u00admiya v\u0259 s.) HbS tap\u0131l\u0131r. Siklinq tes\u00adti\u00adnin pozitiv oldu\u011fu hallarda d\u0259qiq diaq\u00adnoz \u00fc\u00e7\u00fcn d\u0259qiq\u00adl\u0259\u015fdirici testl\u0259r (m\u0259s. Hb elektroforezi) apar\u0131lmal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

OSMOT\u0130K REZ\u0130STENTL\u0130K<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Eritrosit rezistentliyi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a02 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Kalitativ<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz<\/p>\n

Referens:<\/strong>\u00a0X\u0259st\u0259y\u0259 aid n\u0259tic\u0259l\u0259rl\u0259 b\u0259rab\u0259r i\u015fl\u0259nil\u0259n kontrol n\u00fcmun\u0259si m\u00fcqayis\u0259 olunaraq verilir<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Eritrosit rezistentliyinin pozulmas\u0131 ba\u015f ver\u0259n x\u0259st\u0259likl\u0259rin diaq\u00adnozunda istifad\u0259 olunur. Erit\u00adrositl\u0259rin lizis\u0259 u\u011framadan mak\u00adsimum su udma qabiliyy\u0259tini g\u00f6s\u00adt\u0259rir. \u0130rsi sferositoz, irsi stoma\u00adto\u00adsi\u00adtoz, hemolitik anemiyalar, mexaniki travmalar (m\u0259s. prostatik \u00fcr\u0259k qa\u00adpaqc\u0131\u011f\u0131) v\u0259 ferment \u00e7at\u0131\u015fmaz\u00adl\u0131q\u00adla\u00adr\u0131nda (m\u0259s. G6PD) osmotik rezis\u00adtentlik art\u0131r, hipoxrom-mikrositar ane\u00admiyalar (m\u0259s. d\u0259mir \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 anemiyas\u0131, talasemiya), qaraciy\u0259r x\u0259s\u0259likl\u0259ri,\u00a0 polisitemiya vera, sple\u00adnek\u00adtomiyadan sonra v\u0259 leptositozda is\u0259 osmotik rezistentlik azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PAROKS\u0130ZMAL NOKTURNAL HEMOQLOB\u0130NUR\u0130YA<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0PNH<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Flow cytometry<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Lax\u00adtalanm\u0131\u015f, uzun m\u00fcdd\u0259t saxlan\u0131lm\u0131\u015f v\u0259 dondurulmu\u015f n\u00fcmun\u0259l\u0259r<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>PNH damar daxilind\u0259 eritrositl\u0259rin hemolizi, hemoqlobinin sidikl\u0259 ifraz\u0131 v\u0259 damardaxili lax\u00adta\u00adlan\u00adma il\u0259 xarakteriz\u0259 olunan he\u00admopoetik k\u00f6k h\u00fcceyr\u0259 x\u0259st\u0259liyidir. Flow cytometr-d\u0259 CD55 v\u0259 CD59 yoxlu\u011funun a\u015fkar olunmas\u0131, HAM tezti v\u0259 sidikd\u0259 hemosiderin pa\u00adrok\u00adsizmal nokturnal hemo\u00adqlobi\u00adnu\u00adriyan\u0131n diaqnozunda istifad\u0259 olunur. PNH-li x\u0259st\u0259l\u0259rin bir hiss\u0259si aplastik anemiya kimi klinik \u0259lam\u0259tl\u0259r verir. Buna g\u00f6r\u0259 d\u0259 aplastik anemiyal\u0131 x\u0259st\u0259l\u0259rin PNH bax\u0131m\u0131ndan ara\u015f\u00add\u0131r\u0131lmas\u0131 t\u00f6vsiy\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PARS\u0130AL TROMBOPLAST\u0130N ZAMANI (AKT\u0130V PARS\u0130AL TROMBOPLAST\u0130N ZAMANI)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>aPTT, Parsial trombo\u00adplas\u00adtin zaman\u0131, PTT<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:\u00a0<\/strong>mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcl<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>n\u00fc\u00admu\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admo\u00adliz\u0259 u\u011framadan tez ayr\u0131lmal\u0131 v\u0259 so\u00adyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir.\u00a0X\u0259st\u0259nin haz\u0131rlanmas\u0131:\u00a0<\/strong>X\u0259st\u0259 he\u00adparin q\u0259bul edirs\u0259 n\u00f6vb\u0259ti dozadan 1 saat \u0259vv\u0259l n\u00fcmun\u0259 al\u0131nmal\u0131d\u0131r. He\u00adparin vurulan qoldan qan al\u0131nma\u00admal\u0131d\u0131r.<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>Lax\u00adtalanm\u0131\u015f, hemolizli, heparinli n\u00fcmu\u00adn\u0259l\u0259r, uy\u011fun olmayan qan\/anti-koauqulyant nisb\u0259ti<\/p>\n

Referens:\u00a0<\/strong>25-36 san<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Daxili\u00a0(<\/strong>intrensek) laxta\u00adlanma sisteminin qiym\u0259tl\u0259ndirilm\u0259si, heparin m\u00fcalic\u0259sinin n\u0259zar\u0259td\u0259 sax\u00adlan\u0131lmas\u0131, A v\u0259 B hemofiliyan\u0131n skri\u00adninqi, II, V, VIII, IX, X, XI v\u0259 XII faktorlar\u0131n kongenital \u00e7at\u0131\u015fmazl\u0131q\u00adla\u00adr\u0131n\u0131n skrininqi, DIC, disfibrino\u00adge\u00adne\u00admiya, qaraciy\u0259r \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, d\u00f6vr ed\u0259n anti-koaqulyantlar v\u0259 K vita\u00admini \u00e7at\u0131\u015fmazl\u0131\u011f\u0131n\u0131n qiym\u0259tl\u0259ndiril\u00adm\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PLATELET SAYI (TROMBOS\u0130T SAYI)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Platelet miqdar\u0131<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan v\u0259 periferik yaxma preparat\u0131<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6b\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Cell counter (h\u00fcceyr\u0259 say\u0131lmas\u0131) +mikroskopik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n
3 ya\u015f<\/td>\n130-400 K\/mm3<\/sup><\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n180-510 K\/mm3<\/sup><\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n160-510 K\/mm3<\/sup><\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n170-405 K\/mm3<\/sup><\/td>\n<\/tr>\n
15 ya\u015f<\/td>\n130-400 K\/mm3<\/sup><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Laxtalanma sistemi v\u0259 hemostaz poz\u011funluqlar\u0131n\u0131n qiym\u0259t\u00adl\u0259ndirilm\u0259\u0131sind\u0259 istifad\u0259 olunur. B\u0259dxass\u0259li t\u00f6r\u0259m\u0259l\u0259r, mielopro\u00adli\u00adferativ x\u0259st\u0259likl\u0259r, splenektomiyadan sonrak\u0131 v\u0259ziyy\u0259t, revmatoid artrit, d\u0259mir \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 anemiyas\u0131 v\u0259 k\u0259skin infeksiyalar zaman\u0131 trom\u00adbositl\u0259rin miqdar\u0131 art\u0131r, idiopatik trombositopenik purpura (ITP), leykozlar, aplastik v\u0259 pernisitoz anemiya, hipersplenizm, trombotik trombositopenik purpura, massiv qan transfuziyalar\u0131, b\u0259zi infeksiyalar v\u0259 s\u00fcm\u00fck iliyi f\u0259aliyy\u0259tinin z\u0259ifl\u0259m\u0259si il\u0259 trombosit say\u0131 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PLAZMA AKSELERATOR QLOBUL\u0130N (FAKTOR V)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>AC globulin; Labil faktor; Plazma akselerator globulin; Pro\u00adakselerin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan qan\/antikoaqulyant nis\u00adb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fc\u00admun\u0259l\u0259r<\/p>\n

Referens:<\/strong>\u00a0Normal aktivliyin\u00a0 50-150 %-i<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>V faktorun\u00a0 irsi \u00e7at\u0131\u00ad\u015f\u00admaz\u00adl\u0131\u011f\u0131 olan x\u0259st\u0259l\u0259rd\u0259 (parahe\u00admofiliya) anormal qanaxmalar m\u00fc\u015fahid\u0259 olu\u00adnur v\u0259 laxtalanma zaman\u0131, PT v\u0259 APTT testl\u0259rind\u0259 uzanmalar m\u00fc\u0259y\u00ady\u0259n edilir. Hamil\u0259lik zaman\u0131 bir s\u0131ra laxtalanma faktorlar\u0131 kimi V faktor\u00adda da az miqdarda art\u0131m ba\u015f ver\u0259 bil\u0259r. K\u0259skin qaraciy\u0259r \u00e7at\u0131\u015fmazl\u0131\u00ad\u011f\u0131nda sintezin z\u0259ifl\u0259m\u0259si, DDL za\u00adman\u0131 is\u0259 s\u0259rf olunman\u0131n artmas\u0131 il\u0259 \u0259laq\u0259dar olaraq V faktorun miqdar\u0131 azal\u0131r. V faktorun t\u0259yini qaraciy\u0259r x\u0259st\u0259liyi v\u0259 K vitamini \u00e7at\u0131\u015fmaz\u00adl\u0131\u011f\u0131n\u0131n differensiasiyas\u0131nda istifad\u0259 olunur. Parenximal qaraciy\u0259r x\u0259st\u0259\u00adlik\u00adl\u0259rind\u0259 V faktor v\u0259 K vita\u00admi\u00adnin\u00add\u0259n as\u0131l\u0131 sintez olunan laxtalanma faktorlar\u0131 (II, VII, IX v\u0259 X faktorlar) azald\u0131\u011f\u0131 halda, K vitamini \u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u011f\u0131nda V faktor normal, dig\u0259r fak\u00adtorlar\u0131n miqdar\u0131 is\u0259 a\u015fa\u011f\u0131 olur. Bu m\u0259q\u00ads\u0259dl\u0259 V v\u0259 VII faktorlar\u0131n aktiv\u00adliyi t\u0259yin oluna bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PLAZMA TROMBOPLAST\u0130N ANTESEDAN (FAKTOR XI)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Plazma tromboplastin an\u00adte\u00adsedan<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan tez ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Risk qiy\u00adm\u0259t\u00adl\u0259ndirm\u0259 apar\u0131ld\u0131qdan sonra he\u00adparin m\u00fcalic\u0259si m\u00fcayin\u0259d\u0259n 2 g\u00fcn \u0259vv\u0259l k\u0259silm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u011fun olmayan qan\/antikoaqulyant nisb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n
Normal aktivliyin %-i<\/td>\n<7g\u00fcn<\/td>\n20-50<\/td>\n<\/tr>\n
7g\u00fcn-1ay<\/td>\n25-70<\/td>\n<\/tr>\n
2-3ay<\/td>\n40-100<\/td>\n<\/tr>\n
4-6ay<\/td>\n50-130<\/td>\n<\/tr>\n
>60ay<\/td>\n50-150<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

trong>\u0130stifad\u0259si: Homoziqot XI faktor \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 olan x\u0259st\u0259l\u0259rd\u0259 laxtalanma zaman\u0131 v\u0259 APTT uzan\u0131r, d\u0259yi\u015fk\u0259n qanaxma m\u0259nz\u0259r\u0259si m\u00fc\u015fahid\u0259 olunur. PT, TT, trombosit say\u0131 v\u0259 trombositl\u0259rin funksional testl\u0259ri is\u0259 normald\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PLAZM\u0130NOGEN<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0N\u00fc\u00admu\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan qan\/ antikoaqulyant nisb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:<\/strong>\u00a055-145 %<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u0130rsi plazminogen \u00e7at\u0131\u015f\u00admazl\u0131\u011f\u0131 venoz tromboza meyillikl\u0259 \u0259laq\u0259lidir. H\u0259m\u00e7inin qaraciy\u0259r x\u0259s\u00adt\u0259liyi, DIC v\u0259 trombolitik m\u00fcalic\u0259 zaman\u0131 da plazminogen s\u0259viyy\u0259sind\u0259 azalma ba\u015f ver\u0259bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PROAKSELER\u0130N (FAKTOR V)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>AC globulin; Labil faktor; Plazma akselerator globulin; Pro\u00adakselerin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan qan\/antikoaqulyant nis\u00adb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fc\u00admun\u0259l\u0259r<\/p>\n

Referens:<\/strong>\u00a0Normal aktivliyin\u00a0 50-150 %-i<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>V faktorun\u00a0 irsi \u00e7at\u0131\u00ad\u015f\u00admaz\u00adl\u0131\u011f\u0131 olan x\u0259st\u0259l\u0259rd\u0259 (parahe\u00admofiliya) anormal qanaxmalar m\u00fc\u015fahid\u0259 olu\u00adnur v\u0259 laxtalanma zaman\u0131, PT v\u0259 APTT testl\u0259rind\u0259 uzanmalar m\u00fc\u0259y\u00ady\u0259n edilir. Hamil\u0259lik zaman\u0131 bir s\u0131ra laxtalanma faktorlar\u0131 kimi V faktor\u00adda da az miqdarda art\u0131m ba\u015f ver\u0259 bil\u0259r. K\u0259skin qaraciy\u0259r \u00e7at\u0131\u015fmazl\u0131\u00ad\u011f\u0131nda sintezin z\u0259ifl\u0259m\u0259si, DDL za\u00adman\u0131 is\u0259 s\u0259rf olunman\u0131n artmas\u0131 il\u0259 \u0259laq\u0259dar olaraq V faktorun miqdar\u0131 azal\u0131r. V faktorun t\u0259yini qaraciy\u0259r x\u0259st\u0259liyi v\u0259 K vitamini \u00e7at\u0131\u015fmaz\u00adl\u0131\u011f\u0131n\u0131n differensiasiyas\u0131nda istifad\u0259 olunur. Parenximal qaraciy\u0259r x\u0259st\u0259\u00adlik\u00adl\u0259rind\u0259 V faktor v\u0259 K vita\u00admi\u00adnin\u00add\u0259n as\u0131l\u0131 sintez olunan laxtalanma faktorlar\u0131 (II, VII, IX v\u0259 X faktorlar) azald\u0131\u011f\u0131 halda, K vitamini \u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u011f\u0131nda V faktor normal, dig\u0259r fak\u00adtorlar\u0131n miqdar\u0131 is\u0259 a\u015fa\u011f\u0131 olur. Bu m\u0259q\u00ads\u0259dl\u0259 V v\u0259 VII faktorlar\u0131n aktiv\u00adliyi t\u0259yin oluna bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PROKONVERT\u0130N (FAKTOR VII)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Autoprotrombin I; Pro\u00adkon\u00advertin; Stabil faktor\u00a0<\/strong><\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan tez ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:\u00a0<\/strong>Risk qiym\u0259t\u00adl\u0259ndirilm\u0259si apar\u0131ld\u0131qdan son\u00adra ku\u00adma\u00addin cinsli antikoaqulyant istifad\u0259 ed\u0259n x\u0259s\u00adt\u0259l\u0259rd\u0259 2 h\u0259ft\u0259, heparin m\u00fcali\u00adc\u0259\u00adsin\u00add\u0259 is\u0259 2 g\u00fcn \u0259vv\u0259l m\u00fcalic\u0259 k\u0259silm\u0259\u00adlidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Kaoqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>Uy\u00ad\u011fun olmayan qan\/antikoaqulyant nis\u00adb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:\u00a0<\/strong>Normal aktivliyin 50-150%-i<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>VII faktorun \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, nadir rast g\u0259lin\u0259n, autosom resessiv ke\u00e7\u0259n irsi x\u0259st\u0259likdir. X\u0259st\u0259lik olan \u015f\u0259xsl\u0259rd\u0259 PT uzan\u0131r, APTT is\u0259 nor\u00admal olur. Klinik qanaxman\u0131n \u015fidd\u0259ti VII faktorun aktivlik s\u0259viyy\u0259si il\u0259 \u0259la\u00adq\u0259\u00addard\u0131r. Qaraciy\u0259r x\u0259st\u0259liyi v\u0259 K vita\u00admini \u00e7at\u0131\u015fmazn\u0131\u011f\u0131n\u0131n differen\u00adsiasi\u00adya\u00ads\u0131ndada istifad\u0259 olunur. Pa\u00adrenximal qaraciy\u0259r x\u0259st\u0259likl\u0259rind\u0259 V faktor v\u0259 K vitaminind\u0259n as\u0131l\u0131 sintez olunan lax\u00adta\u00adlanma faktorlar\u0131 (II, VII, IX v\u0259 X) azal\u00add\u0131\u011f\u0131 halda, K vitamini \u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u011f\u0131nda V faktor normal, di\u00adg\u0259r faktor s\u0259viyy\u0259l\u0259ri is\u0259 a\u015fa\u011f\u0131 olur. Bu m\u0259qs\u0259dl\u0259 V v\u0259 VII faktorlar\u0131n ak\u00adtivliyi t\u0259yin oluna bil\u0259r. Oral kon\u00adtraseptiv istifad\u0259 ed\u0259n qad\u0131nlar\u0131n plazmalar\u0131 4o<\/sup>C-d\u0259 sax\u00adlan\u0131ld\u0131qda VII faktorun aktivliyind\u0259 10 d\u0259f\u0259y\u0259 q\u0259\u00add\u0259r art\u0131m m\u00fc\u015fahid\u0259 oluna bil\u0259r. H\u0259m\u00ad\u00e7inin VII faktorun aktiv\u00adliyinin artmas\u0131 miokard infarkt\u0131 riskini d\u0259 art\u0131r\u0131r. Oral antikoaqulyantlar\u0131n is\u00adtifad\u0259si, a\u011f\u0131r qaraciy\u0259r x\u0259st\u0259liyi v\u0259 K vitamini \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 hallar\u0131nda is\u0259 VII faktorun s\u0259viyy\u0259sind\u0259 azalmalar m\u00fc\u00ad\u015fahid\u0259 oluna bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PROTE\u0130N C AKT\u0130VL\u0130Y\u0130<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Protein C funksional<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admo\u00adliz\u0259 u\u011framadan d\u0259rhal ayr\u0131lmal\u0131 v\u0259 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259\u00adrilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Kumadin cinsli antikoaqulyant istifad\u0259 ed\u0259n x\u0259st\u0259l\u0259rd\u0259 2 h\u0259ft\u0259, heparin m\u00fcalic\u0259sind\u0259 is\u0259 2 g\u00fcn \u0259vv\u0259lc\u0259d\u0259n m\u00fcalic\u0259 dayand\u0131r\u0131lmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u011fun olmayan qan\/antikoaqulyant nisb\u0259ti, laxtalanm\u0131\u015f, hemoliz\u0259 u\u011f\u00adram\u0131\u015f, heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
<6 ay<\/td>\n15-140 %<\/td>\n<\/tr>\n
>6 ay<\/td>\n70-140 %<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Anadang\u0259lm\u0259 v\u0259 qa\u00adzan\u0131lma protein C \u00e7at\u0131\u015fmazl\u0131qlar\u0131n\u0131n t\u0259yinind\u0259 istifad\u0259 olunur. Protein C \u00e7at\u0131\u015fmazl\u0131qlar\u0131nda tromboza meyillik art\u0131r. Diabet, nefrotik sindrom, ha\u00admil\u0259lik v\u0259 oral kontraseptiv isti\u00adfad\u0259sind\u0259 protein C aktivliyi art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PROTE\u0130N C ANT\u0130GEN\u0130<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan d\u0259rhal ayr\u0131lmal\u0131 v\u0259 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0RID<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u011fun olmayan qan\/antikoaqulyant nisb\u0259ti, laxtalanm\u0131\u015f, hemoliz\u0259 u\u011f\u00adram\u0131\u015f, heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:<\/strong>\u00a01.82-3.90 mg\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Anadang\u0259lm\u0259 v\u0259 qa\u00adzan\u0131lma protein C \u00e7at\u0131\u015fmazl\u0131qlar\u0131n\u0131n t\u0259yinind\u0259 v\u0259 tipl\u0259ndirilm\u0259sind\u0259 isti\u00adfad\u0259 olunur. Protein C \u00e7at\u0131\u015fmaz\u00adl\u0131qlar\u0131nda tromboza meyllilik art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PROTE\u0130N C FUNKS\u0130ONAL (PROTE\u0130N C AKT\u0130VL\u0130Y\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Protein C funksional<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admo\u00adliz\u0259 u\u011framadan d\u0259rhal ayr\u0131lmal\u0131 v\u0259 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259\u00adrilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Kumadin cinsli antikoaqulyant istifad\u0259 ed\u0259n x\u0259st\u0259l\u0259rd\u0259 2 h\u0259ft\u0259, heparin m\u00fcalic\u0259sind\u0259 is\u0259 2 g\u00fcn \u0259vv\u0259lc\u0259d\u0259n m\u00fcalic\u0259 dayand\u0131r\u0131lmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u011fun olmayan qan\/antikoaqulyant nisb\u0259ti, laxtalanm\u0131\u015f, hemoliz\u0259 u\u011f\u00adram\u0131\u015f, heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
<6 ay<\/td>\n15-140 %<\/td>\n<\/tr>\n
>6 ay<\/td>\n70-140 %<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Anadang\u0259lm\u0259 v\u0259 qa\u00adzan\u0131lma protein C \u00e7at\u0131\u015fmazl\u0131qlar\u0131n\u0131n t\u0259yinind\u0259 istifad\u0259 olunur. Protein C \u00e7at\u0131\u015fmazl\u0131qlar\u0131nda tromboza meyillik art\u0131r. Diabet, nefrotik sindrom, ha\u00admil\u0259lik v\u0259 oral kontraseptiv isti\u00adfad\u0259sind\u0259 protein C aktivliyi art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PROTE\u0130N S AKT\u0130V\u0130TL\u0130Y\u0130<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0protein S funksional<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>300 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259ril\u00adm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Kumadin tipli antikoaqulyant istifad\u0259 ed\u0259n x\u0259st\u0259l\u0259rd\u0259 2 h\u0259ft\u0259, heparin m\u00fcali\u00adc\u0259sind\u0259 is\u0259 2 g\u00fcn \u0259vv\u0259lc\u0259d\u0259n m\u00fcali\u00adc\u0259 dayand\u0131r\u0131lmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u011fun olmayan qan \/ antikoaqulyant nisb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
<6 ay<\/td>\n15-160%<\/td>\n<\/tr>\n
>6 ay<\/td>\n15-160%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Anadang\u0259lm\u0259 v\u0259 qaza\u00adn\u0131lma protein S \u00e7at\u0131\u015fmazl\u0131qlar\u0131n\u0131n t\u0259yinind\u0259 istifad\u0259 olunur. Protein S \u00e7at\u0131\u015fmazl\u0131qlar\u0131nda tromboza meyillik art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PROTE\u0130N S ANT\u0130GEN\u0130<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 ml<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>R\u0130D<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u011fun olmayan qan \/ antikoaqulyant nisb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:<\/strong>12-21mg\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Anadang\u0259lm\u0259 v\u0259 qaza\u00adn\u0131lm\u0131\u015f protein S \u00e7at\u0131\u015fmazl\u0131qlar\u0131n\u0131n t\u0259yinind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PROTE\u0130N S FUNKS\u0130ONAL (PROTE\u0130N S AKT\u0130V\u0130TL\u0130Y\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0protein S funksional<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>300 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259ril\u00adm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Kumadin tipli antikoaqulyant istifad\u0259 ed\u0259n x\u0259st\u0259l\u0259rd\u0259 2 h\u0259ft\u0259, heparin m\u00fcali\u00adc\u0259sind\u0259 is\u0259 2 g\u00fcn \u0259vv\u0259lc\u0259d\u0259n m\u00fcali\u00adc\u0259 dayand\u0131r\u0131lmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u011fun olmayan qan \/ antikoaqulyant nisb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
<6 ay<\/td>\n15-160%<\/td>\n<\/tr>\n
>6 ay<\/td>\n15-160%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Anadang\u0259lm\u0259 v\u0259 qaza\u00adn\u0131lma protein S \u00e7at\u0131\u015fmazl\u0131qlar\u0131n\u0131n t\u0259yinind\u0259 istifad\u0259 olunur. Protein S \u00e7at\u0131\u015fmazl\u0131qlar\u0131nda tromboza meyillik art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PROTROMB\u0130N AKT\u0130VL\u0130Y\u0130 (FAKTOR II)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Protrombin aktivliyi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratli plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fcm\u00adun\u0259 al\u0131nd\u0131qdan sonra plazma hemo\u00adliz\u0259 u\u011framadan tez ayr\u0131lmal\u0131 v\u0259 so\u00adyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:\u00a0<\/strong>Risk qiy\u00adm\u0259tl\u0259ndirilm\u0259si apar\u0131ld\u0131qdan sonra komadin cinsli antikoaqulyant isti\u00adfad\u0259 ed\u0259n x\u0259st\u0259l\u0259r 2 h\u0259ft\u0259, heparin m\u00fca\u00adlic\u0259si alanlar is\u0259 2 g\u00fcn \u0259vv\u0259ld\u0259n m\u00fcalic\u0259ni dayand\u0131rmal\u0131d\u0131rlar<\/p>\n

\u0130\u015f prinsipi:<\/strong>Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>\u00a0Uy\u00ad\u011fun olmayan qan\/antikoaqulyant nisb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:\u00a0<\/strong>Normal aktivliyin 50-150 %-i<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Protrombin zaman\u0131 il\u0259 ey\u00adni test kimi qiym\u0259tl\u0259ndirilm\u0259\u00adm\u0259\u00adlidir. \u0130rsi protrombin \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 ol\u00adduqca nadir rast g\u0259lin\u0259n koaquli\u00adya\u00adsiya poz\u00ad\u011funlu\u011fudur. Autosom reses\u00adsiv me\u00adxa\u00adnizml\u0259 ke\u00e7\u0259n bu poz\u011funluq zaman\u0131 orqanizmd\u0259 m\u00fct\u0259lif d\u0259r\u0259c\u0259l\u0259rd\u0259 qan\u00adaxmaya meyillik olur. Bu \u015f\u0259xsl\u0259rd\u0259 PT v\u0259 aPTT testl\u0259rind\u0259 uzanma m\u00fc\u00ad\u015fahid\u0259 edilir. H\u0259m\u00e7inin K vitamini \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 v\u0259 oral antikoaquliyant m\u00fcalic\u0259si protrombin s\u0259viyy\u0259l\u0259rini azald\u0131r. Protrombin s\u0259viyy\u0259l\u0259rinin y\u00fcks\u0259kliyi is\u0259 protrombin genind\u0259ki mutasiyan\u0131n n\u0259tic\u0259si kimi inki\u015faf edir v\u0259 tromboz riskini art\u0131r\u0131r. Bel\u0259 hallarda x\u0259st\u0259d\u0259 kardiovaskulyar risk faktorlar\u0131 da varsa, miokard infarkt\u0131 eh\u00adtimal\u0131 art\u0131r. 115% aktivlikd\u0259n yu\u00adxar\u0131 n\u0259tic\u0259l\u0259r is\u0259 risk kimi q\u0259bul edilmir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PROTROMB\u0130N ZAMANI<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0PTZ<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u011fun olmayan qan \/ antikoaqulyant nisb\u0259ti, laxtal\u0131, hemolizli. heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:<\/strong>\u00a010.0-13.5 saniy\u0259; 0.85-1.20 INR<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Protrombin zaman\u0131\u00a0 xarici yolun g\u00f6st\u0259ricisidir. Ad\u0259t\u0259n oral anti\u00adkoaqulyant m\u00fcalic\u0259sinin izl\u0259nil\u00adm\u0259sind\u0259 istifad\u0259 olunur. H\u0259m\u00e7inin II,V,VII v\u0259 X faktorun anadang\u0259lm\u0259 \u00e7at\u0131\u015fmazl\u0131q\u0131ar\u0131, disfibrino\u00adgenemiya, qaraciy\u0259r \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, DIC v\u0259 K vitamini\u00a0 \u00e7at\u0131\u015fmazl\u0131\u011f\u0131n\u0131n ara\u015fd\u0131r\u0131l\u00admas\u0131nda da faydal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PTT (AKT\u0130V PARS\u0130AL TROMBOPLAST\u0130N ZAMANI)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>aPTT, Parsial trombo\u00adplas\u00adtin zaman\u0131, PTT<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:\u00a0<\/strong>mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcl<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>n\u00fc\u00admu\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admo\u00adliz\u0259 u\u011framadan tez ayr\u0131lmal\u0131 v\u0259 so\u00adyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir.\u00a0X\u0259st\u0259nin haz\u0131rlanmas\u0131:\u00a0<\/strong>X\u0259st\u0259 he\u00adparin q\u0259bul edirs\u0259 n\u00f6vb\u0259ti dozadan 1 saat \u0259vv\u0259l n\u00fcmun\u0259 al\u0131nmal\u0131d\u0131r. He\u00adparin vurulan qoldan qan al\u0131nma\u00admal\u0131d\u0131r.<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>Lax\u00adtalanm\u0131\u015f, hemolizli, heparinli n\u00fcmu\u00adn\u0259l\u0259r, uy\u011fun olmayan qan\/anti-koauqulyant nisb\u0259ti<\/p>\n

Referens:\u00a0<\/strong>25-36 san<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Daxili\u00a0(<\/strong>intrensek) laxta\u00adlanma sisteminin qiym\u0259tl\u0259ndirilm\u0259si, heparin m\u00fcalic\u0259sinin n\u0259zar\u0259td\u0259 sax\u00adlan\u0131lmas\u0131, A v\u0259 B hemofiliyan\u0131n skri\u00adninqi, II, V, VIII, IX, X, XI v\u0259 XII faktorlar\u0131n kongenital \u00e7at\u0131\u015fmazl\u0131q\u00adla\u00adr\u0131n\u0131n skrininqi, DIC, disfibrino\u00adge\u00adne\u00admiya, qaraciy\u0259r \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, d\u00f6vr ed\u0259n anti-koaqulyantlar v\u0259 K vita\u00admini \u00e7at\u0131\u015fmazl\u0131\u011f\u0131n\u0131n qiym\u0259tl\u0259ndiril\u00adm\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PTT-LA (LUPUS ANT\u0130KOAQULYANT SKR\u0130N\u0130NQ)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0PTT-LA; LA-DVV; dRVVT testi; Dilite Russell viper venom time<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259ril\u00adm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan qan \/ antikoaqulyant miqdar\u0131, laxtal\u0131, hemolizli heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:<\/strong>\u00a0Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Lupus anticisiml\u0259ri, SLE, trombotik hallar, t\u0259krarlanan d\u00f6l it\u00adkil\u0259ri, trombositopeniya v\u0259 m\u00fcxt\u0259lif nevroloji poz\u011funluqlarla \u0259laq\u0259lidir. Dig\u0259r autoimmun poz\u011funluqlar, b\u0259d\u00adxass\u0259li t\u00f6r\u0259m\u0259l\u0259r, infeksiyalar v\u0259 b\u0259\u00adzi d\u0259rmanlar\u0131n istifad\u0259sind\u0259 d\u0259 (m\u0259s. fenotiazinl\u0259r v\u0259 \u00fcr\u0259k antiaritmik preparatlar\u0131) lupus antikoaqulyantlar\u0131 tap\u0131la bil\u0259r. Bu x\u0259st\u0259l\u0259rd\u0259 aPTT kimi fosfolipid as\u0131l\u0131 in vitro laxtalanma testl\u0259rind\u0259 uzanma ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

QAN QRUPLARI V\u018f RH T\u018fY\u0130N\u0130<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0ABO qruplar\u0131<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>X\u0259s\u00adt\u0259\u00adnin ad\u0131 m\u00fctl\u0259q s\u0131naq \u015f\u00fc\u015f\u0259sinin \u00fcz\u0259\u00adrind\u0259 olmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>S\u0131naq \u015f\u00fc\u015f\u0259sind\u0259 aglu\u00adtinasiya<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Qan qruplar\u0131 v\u0259 Rh tip\u00adl\u0259n\u00addirilm\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

QANAXMA ZAMANI<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Kapillyar qan<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>Labo\u00adratoriyada, x\u0259st\u0259nin oturaq v\u0259ziy\u00ady\u0259tind\u0259 \u00f6l\u00e7\u00fcl\u00fcr<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0\u00d6l\u00e7\u00fcl\u0259c\u0259k nahiy\u0259d\u0259 d\u0259ri taml\u0131\u011f\u0131 pozulmam\u0131\u015f v\u0259 \u00f6demsiz olmal\u0131d\u0131r. Yoxlama apar\u0131\u00adlacaq \u0259l \u00e7ox soyuq olduqda otaq temperaturuna uy\u011funla\u015fana q\u0259d\u0259r g\u00f6zl\u0259m\u0259k laz\u0131md\u0131r<\/p>\n

Referens:<\/strong>\u00a03-7 d\u0259qiq\u0259<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Kapillyar funksiyalar\u0131n, h\u0259m\u00ad\u00e7inin trombositl\u0259rin say\u0131 v\u0259 funk\u00adsiyas\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259sind\u0259 isti\u00adfa\u00add\u0259 olunur. Kapillyar v\u0259 spontan qan\u00adax\u00admalar\u0131n t\u0259yinind\u0259 \u0259h\u0259miyy\u0259t k\u0259sb edir. Aspirin h\u0259ssasl\u0131\u011f\u0131, Glanz\u00adman v\u0259 von Willerbrand x\u0259st\u0259\u00adlik\u00adl\u0259\u00adrin\u00add\u0259 qanaxma zaman\u0131 uzan\u0131r. H\u0259m\u00ad\u00e7inin Bernard\u2013Souler sindromu, ure\u00admiya, birl\u0259\u015fdirici toxuma x\u0259st\u0259\u00adlik\u00adl\u0259\u00adri, irsi telan\u00adgiektaziya v\u0259 qaraciy\u0259r x\u0259st\u0259likl\u0259rind\u0259 d\u0259 qanaxma zaman\u0131 uzana bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

QIRMIZI QAN H\u00dcCEYR\u018fL\u018fR\u0130N\u0130N SAYI (ER\u0130TROS\u0130T SAYI)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Q\u0131rm\u0131z\u0131 qan h\u00fcceyr\u0259\u00adl\u0259\u00adrinin say\u0131; RBC<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admu\u00adn\u0259 al\u0131nark\u0259n turnan\u0131n uzun m\u00fcd\u00add\u0259t qalmas\u0131 s\u0259hv n\u0259tic\u0259l\u0259r\u0259 s\u0259b\u0259b olur<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Saat 17.00-07.00 aras\u0131nda v\u0259 yem\u0259kl\u0259rd\u0259n sonra\u00a0 eritrositl\u0259rin say\u0131nda bir q\u0259d\u0259r\u00a0 azalma m\u00fc\u015fahid\u0259 oluna bil\u0259r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0H\u00fcceyr\u0259 say\u0131lmas\u0131<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0N\u00fc\u00admun\u0259nin laxtalanm\u0131\u015f olmas\u0131<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259sind\u0259n g\u00f6t\u00fcr\u00fclm\u00fc\u015f qan<\/td>\n3.9-5.5 milyon\/mm3<\/sup><\/td>\n<\/tr>\n
Erk\u0259n do\u011fulmu\u015f u\u015faqlarda<\/td>\n3.9-5.5 milyon\/mm3<\/sup><\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n4.0-6.6 milyon\/mm3<\/sup><\/td>\n<\/tr>\n
7 g\u00fcn-1 ay<\/td>\n3.9-6.2 milyon\/mm3<\/sup><\/td>\n<\/tr>\n
2-3 ay<\/td>\n3.0-5.4 milyon\/mm3<\/sup><\/td>\n<\/tr>\n
4-6 ay<\/td>\n3.1-4.5 milyon\/mm3<\/sup><\/td>\n<\/tr>\n
7 ay-3 ya\u015f<\/td>\n3.7-5.3 milyon\/mm3<\/sup><\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n3.9-5.3 milyon\/mm3<\/sup><\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n4.0-5.2 milyon\/mm3<\/sup><\/td>\n<\/tr>\n
\u00a0<\/strong><\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n4.5-5.3 milyon\/mm3<\/sup><\/td>\n4.1-5.1 milyon\/mm3<\/sup><\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n4.5-5.9 milyon\/mm3<\/sup><\/td>\n4.0-5.2 milyon\/mm3<\/sup><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Polisitemiya, a\u011f\u0131r idman, hemokonsentrasiya v\u0259 y\u00fcks\u0259k\u00adlik\u00adl\u0259r\u00add\u0259 eritrositl\u0259rin say\u0131 art\u0131r, anemiyalar v\u0259 hemoliz\u0259 s\u0259b\u0259b olan b\u0259zi d\u0259rman\u00adlar\u0131n q\u0259bulu zaman\u0131 is\u0259 eritrositl\u0259rin say\u0131 azala bil\u0259r. Bunlardan ba\u015fqa, so\u00adyuq aqql\u00fctininl\u0259rin varl\u0131\u011f\u0131 da yaln\u0131\u015f olaraq eritrositin say\u0131n\u0131n azl\u0131\u011f\u0131na v\u0259 ya avtomatik qan say\u0131m cihazlar\u0131nda say\u0131lmamas\u0131na s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

RBC (ER\u0130TROS\u0130T SAYI)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Q\u0131rm\u0131z\u0131 qan h\u00fcceyr\u0259\u00adl\u0259\u00adrinin say\u0131; RBC<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admu\u00adn\u0259 al\u0131nark\u0259n turnan\u0131n uzun m\u00fcd\u00add\u0259t qalmas\u0131 s\u0259hv n\u0259tic\u0259l\u0259r\u0259 s\u0259b\u0259b olur<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Saat 17.00-07.00 aras\u0131nda v\u0259 yem\u0259kl\u0259rd\u0259n sonra\u00a0 eritrositl\u0259rin say\u0131nda bir q\u0259d\u0259r\u00a0 azalma m\u00fc\u015fahid\u0259 oluna bil\u0259r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0H\u00fcceyr\u0259 say\u0131lmas\u0131<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0N\u00fc\u00admun\u0259nin laxtalanm\u0131\u015f olmas\u0131<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259sind\u0259n g\u00f6t\u00fcr\u00fclm\u00fc\u015f qan<\/td>\n3.9-5.5 milyon\/mm3<\/sup><\/td>\n<\/tr>\n
Erk\u0259n do\u011fulmu\u015f u\u015faqlarda<\/td>\n3.9-5.5 milyon\/mm3<\/sup><\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n4.0-6.6 milyon\/mm3<\/sup><\/td>\n<\/tr>\n
7 g\u00fcn-1 ay<\/td>\n3.9-6.2 milyon\/mm3<\/sup><\/td>\n<\/tr>\n
2-3 ay<\/td>\n3.0-5.4 milyon\/mm3<\/sup><\/td>\n<\/tr>\n
4-6 ay<\/td>\n3.1-4.5 milyon\/mm3<\/sup><\/td>\n<\/tr>\n
7 ay-3 ya\u015f<\/td>\n3.7-5.3 milyon\/mm3<\/sup><\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n3.9-5.3 milyon\/mm3<\/sup><\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n4.0-5.2 milyon\/mm3<\/sup><\/td>\n<\/tr>\n
\u00a0<\/strong><\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n4.5-5.3 milyon\/mm3<\/sup><\/td>\n4.1-5.1 milyon\/mm3<\/sup><\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n4.5-5.9 milyon\/mm3<\/sup><\/td>\n4.0-5.2 milyon\/mm3<\/sup><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Polisitemiya, a\u011f\u0131r idman, hemokonsentrasiya v\u0259 y\u00fcks\u0259k\u00adlik\u00adl\u0259r\u00add\u0259 eritrositl\u0259rin say\u0131 art\u0131r, anemiyalar v\u0259 hemoliz\u0259 s\u0259b\u0259b olan b\u0259zi d\u0259rman\u00adlar\u0131n q\u0259bulu zaman\u0131 is\u0259 eritrositl\u0259rin say\u0131 azala bil\u0259r. Bunlardan ba\u015fqa, so\u00adyuq aqql\u00fctininl\u0259rin varl\u0131\u011f\u0131 da yaln\u0131\u015f olaraq eritrositin say\u0131n\u0131n azl\u0131\u011f\u0131na v\u0259 ya avtomatik qan say\u0131m cihazlar\u0131nda say\u0131lmamas\u0131na s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

RET\u0130KULOS\u0130T SAYI<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0H\u00fcceyr\u0259 say\u0131lmas\u0131<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0N\u00fc\u00admun\u0259nin laxtal\u0131 v\u0259 ya hemolizli olmas\u0131<\/p>\n

Referens:<\/strong>\u00a00.5-2.5%<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Retukulosit say\u0131n\u0131n qiy\u00adm\u0259t\u00adl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olunur. Eritropoezin artd\u0131\u011f\u0131 hallar v\u0259 ane\u00admi\u00adyalar\u0131n m\u00fcalic\u0259si zaman\u0131 retukulosit say\u0131 art\u0131r, aplastik anemiya, b\u00f6yr\u0259k x\u0259st\u0259likl\u0259ri, d\u0259mir \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 ane\u00admiyas\u0131, xroniki x\u0259st\u0259lik anemiyas\u0131, sideroblastik anemiya v\u0259 meqa\u00adloblastik anemiyalarda is\u0259 retikulosit say\u0131 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

R\u0130STOSET\u0130N KOFAKTOR<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0von Willebrand faktor f\u0259aliyy\u0259ti<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500\u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0N\u00fc\u00admu\u00adn\u0259 hemoliz edilm\u0259d\u0259n d\u0259rhal ay\u00adr\u0131l\u00admal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259\u00adrilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Lateks aqql\u00fctinasiya<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan qan\/antikoaqulyant nisb\u0259ti, laxtal\u0131, hemolizli. heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:<\/strong>\u00a050-150%<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u0130nsanlarda \u0259n \u00e7ox rast\u00adlanan anadan g\u0259lm\u0259 qanaxma poz\u00ad\u011funlu\u011fu olan von Willebrand x\u0259s\u00adt\u0259liyinin t\u0259yinind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

SED\u0130MENTAS\u0130YA (ER\u0130TROS\u0130TL\u018fR\u0130N \u00c7\u00d6KM\u018f S\u00dcR\u018fT\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Sedimentasiya; Western \u00e7\u00f6km\u0259 s\u00fcr\u0259ti; ESR, E\u00c7S<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Qara qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01.5 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Qapal\u0131 sistem<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0N\u00fc\u00admu\u00adn\u0259nin laxtal\u0131, hemolizli v\u0259 ya h\u0259d\u00addind\u0259n art\u0131q lipemiyal\u0131 olmas\u0131, uzun m\u00fcdd\u0259t g\u00f6zl\u0259m\u0259si, qan\/sitrat nisb\u0259\u00adtinin d\u00fczg\u00fcn olmamas\u0131 v\u0259 miqda\u00adr\u0131\u00adn\u0131n laz\u0131m olandan az v\u0259 ya \u00e7ox olmas\u0131<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n
Ya\u015f<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
<7g\u00fcn<\/td>\n<10mm\/saat<\/td>\n<10mm\/saat<\/td>\n<\/tr>\n
7g\u00fcn-50ya\u015f<\/td>\n<15mm\/saat<\/td>\n<20mm\/saat<\/td>\n<\/tr>\n
>50ya\u015f<\/td>\n<20mm\/saat<\/td>\n<25mm\/saat<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u0130ltihabi x\u0259st\u0259likl\u0259r, k\u0259skin v\u0259 xroniki infksiyalar, toxuma nek\u00adro\u00adzu, temporal arterit, b\u0259d xass\u0259li t\u00f6r\u0259m\u0259l\u0259r, revmatoid x\u0259st\u0259likl\u0259r v\u0259 autoimmun x\u0259st\u0259likl\u0259rin diaqnoz v\u0259 m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

STAB\u0130L FAKTOR (FAKTOR VII)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Autoprotrombin I; Pro\u00adkon\u00advertin; Stabil faktor\u00a0<\/strong><\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan tez ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:\u00a0<\/strong>Risk qiym\u0259t\u00adl\u0259ndirilm\u0259si apar\u0131ld\u0131qdan son\u00adra ku\u00adma\u00addin cinsli antikoaqulyant istifad\u0259 ed\u0259n x\u0259s\u00adt\u0259l\u0259rd\u0259 2 h\u0259ft\u0259, heparin m\u00fcali\u00adc\u0259\u00adsin\u00add\u0259 is\u0259 2 g\u00fcn \u0259vv\u0259l m\u00fcalic\u0259 k\u0259silm\u0259\u00adlidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Kaoqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>Uy\u00ad\u011fun olmayan qan\/antikoaqulyant nis\u00adb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:\u00a0<\/strong>Normal aktivliyin 50-150%-i<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>VII faktorun \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, nadir rast g\u0259lin\u0259n, autosom resessiv ke\u00e7\u0259n irsi x\u0259st\u0259likdir. X\u0259st\u0259lik olan \u015f\u0259xsl\u0259rd\u0259 PT uzan\u0131r, APTT is\u0259 nor\u00admal olur. Klinik qanaxman\u0131n \u015fidd\u0259ti VII faktorun aktivlik s\u0259viyy\u0259si il\u0259 \u0259la\u00adq\u0259\u00addard\u0131r. Qaraciy\u0259r x\u0259st\u0259liyi v\u0259 K vita\u00admini \u00e7at\u0131\u015fmazn\u0131\u011f\u0131n\u0131n differen\u00adsiasi\u00adya\u00ads\u0131ndada istifad\u0259 olunur. Pa\u00adrenximal qaraciy\u0259r x\u0259st\u0259likl\u0259rind\u0259 V faktor v\u0259 K vitaminind\u0259n as\u0131l\u0131 sintez olunan lax\u00adta\u00adlanma faktorlar\u0131 (II, VII, IX v\u0259 X) azal\u00add\u0131\u011f\u0131 halda, K vitamini \u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u011f\u0131nda V faktor normal, di\u00adg\u0259r faktor s\u0259viyy\u0259l\u0259ri is\u0259 a\u015fa\u011f\u0131 olur. Bu m\u0259qs\u0259dl\u0259 V v\u0259 VII faktorlar\u0131n ak\u00adtivliyi t\u0259yin oluna bil\u0259r. Oral kon\u00adtraseptiv istifad\u0259 ed\u0259n qad\u0131nlar\u0131n plazmalar\u0131 4o<\/sup>C-d\u0259 sax\u00adlan\u0131ld\u0131qda VII faktorun aktivliyind\u0259 10 d\u0259f\u0259y\u0259 q\u0259\u00add\u0259r art\u0131m m\u00fc\u015fahid\u0259 oluna bil\u0259r. H\u0259m\u00ad\u00e7inin VII faktorun aktiv\u00adliyinin artmas\u0131 miokard infarkt\u0131 riskini d\u0259 art\u0131r\u0131r. Oral antikoaqulyantlar\u0131n is\u00adtifad\u0259si, a\u011f\u0131r qaraciy\u0259r x\u0259st\u0259liyi v\u0259 K vitamini \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 hallar\u0131nda is\u0259 VII faktorun s\u0259viyy\u0259sind\u0259 azalmalar m\u00fc\u00ad\u015fahid\u0259 oluna bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

STUART FAKTOR (FAKTOR X)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Stuart faktoru; auto\u00adpro\u00adtrombin C; autoprotrombin III<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admu\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan tez ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Risk qiy\u00adm\u0259tl\u0259ndirilm\u0259 apar\u0131ld\u0131qdan sonra ku\u00admadin cinsli antikoaqulyant istifad\u0259 ed\u0259n x\u0259st\u0259l\u0259rd\u0259 2 h\u0259ft\u0259, heparin m\u00fca\u00adli\u00adc\u0259\u00adsind\u0259 is\u0259 2 g\u00fcn \u0259vv\u0259l m\u00fca\u00adlic\u0259 k\u0259silm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan qan\/antikoaqul\u00adyant\u00adnisb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:\u00a0<\/strong>Normal aktivliyin 50-150%-i<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u0130rsi X faktor \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 olan x\u0259st\u0259l\u0259rd\u0259 PT v\u0259 APTT uzanm\u0131\u015f, TT is\u0259 normald\u0131r. X faktor \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 autosom resessiv ke\u00e7ir. Qazan\u0131lm\u0131\u015f X faktor \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 is\u0259 birincili amiloidoz il\u0259 \u0259laq\u0259dard\u0131r. Bundan ba\u015fqa, oral antikoaqul\u00adyant\u00adlar\u0131n istifad\u0259si v\u0259 K vitamini \u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u011f\u0131nda da X faktorun miqdar\u0131 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TAM QAN SAYILMASI<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Complete blood count; CBC; Hemoqram, qanin \u00fcmumi analizi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Cell counter (h\u00fcceyr\u0259 say\u0131lmas\u0131)<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0N\u00fc\u00admun\u0259nin laxtal\u0131 olmas\u0131<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Hematoloji x\u0259st\u0259likl\u0259r, k\u0259s\u00adkin v\u0259 xroniki infeksiyalar, \u0259m\u0259\u00adliy\u00adyatdan \u0259vv\u0259l v\u0259 s. hallarda istifad\u0259 olunur. X\u0259st\u0259nin \u00fcmumi sa\u011flaml\u0131q v\u0259ziyy\u0259ti haqq\u0131nda m\u0259lumat verir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TROMB\u0130N ZAMANI<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Trombin laxtalanma zaman\u0131<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u011fun olmayan qan\/antikoaqulyant nisb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:<\/strong>\u00a014-18 saniy\u0259<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Hipofibrinogenemiya v\u0259 heparin\u0259 b\u0259nz\u0259r antikoaqul\u00adyant\u00adlar\u0131n varl\u0131\u011f\u0131n\u0131n t\u0259yinind\u0259, streptokinaza il\u0259 m\u00fcalic\u0259nin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TROMBOS\u0130T ANT\u0130C\u0130S\u0130M\u0130 (ANT\u0130-TROMBOS\u0130T ANT\u0130C\u0130S\u0130M\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Trombosit anticisimi; An\u00adti-trombosit\u00a0 anticisimi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0EDTA-l\u0131 v\u0259 ya sitratl\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi (EDTA-l\u0131) v\u0259 ya mavi (sitratl\u0131) qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259\u00adsi<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>5 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Flow cytometry<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>Lax\u00adtalanma, hemoliz<\/p>\n

Referens:\u00a0<\/strong>\u00a0Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>\u0130mmun trombosito\u00adpeni\u00adya\u00adlar zaman\u0131 trombosit antisim\u00adl\u0259rinin t\u0259yinind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TROMBOS\u0130T SAYI<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Platelet miqdar\u0131<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan v\u0259 periferik yaxma preparat\u0131<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6b\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Cell counter (h\u00fcceyr\u0259 say\u0131lmas\u0131) +mikroskopik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n
3 ya\u015f<\/td>\n130-400 K\/mm3<\/sup><\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n180-510 K\/mm3<\/sup><\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n160-510 K\/mm3<\/sup><\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n170-405 K\/mm3<\/sup><\/td>\n<\/tr>\n
15 ya\u015f<\/td>\n130-400 K\/mm3<\/sup><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Laxtalanma sistemi v\u0259 hemostaz poz\u011funluqlar\u0131n\u0131n qiym\u0259t\u00adl\u0259ndirilm\u0259\u0131sind\u0259 istifad\u0259 olunur. B\u0259dxass\u0259li t\u00f6r\u0259m\u0259l\u0259r, mielopro\u00adli\u00adferativ x\u0259st\u0259likl\u0259r, splenektomiyadan sonrak\u0131 v\u0259ziyy\u0259t, revmatoid artrit, d\u0259mir \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 anemiyas\u0131 v\u0259 k\u0259skin infeksiyalar zaman\u0131 trom\u00adbositl\u0259rin miqdar\u0131 art\u0131r, idiopatik trombositopenik purpura (ITP), leykozlar, aplastik v\u0259 pernisitoz anemiya, hipersplenizm, trombotik trombositopenik purpura, massiv qan transfuziyalar\u0131, b\u0259zi infeksiyalar v\u0259 s\u00fcm\u00fck iliyi f\u0259aliyy\u0259tinin z\u0259ifl\u0259m\u0259si il\u0259 trombosit say\u0131 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TUR\u015eU HEMOL\u0130Z TEST\u0130 (HAM TEST\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Tur\u015fu hemolizi testi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>X\u0259st\u0259d\u0259n v\u0259 eyni qan qruplu sa\u011flam \u015f\u0259xsd\u0259n EDTA-l\u0131 tam qan v\u0259 serum g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum) v\u0259 b\u0259n\u00f6v\u015f\u0259yi qa\u00adpaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (EDTA-l\u0131 tam qan)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>3 mL EDTA-l\u0131 tam qan v\u0259 3mL serum<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Kvalitativ<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Paroksizmal nokturnal (gec\u0259) hemoqlobinuriyan\u0131n t\u0259yinind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

VON WILLERBAND FAKTOR AKT\u0130VL\u0130Y\u0130 (R\u0130STOSET\u0130N KOFAKTOR)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0von Willebrand faktor f\u0259aliyy\u0259ti<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500\u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0N\u00fc\u00admu\u00adn\u0259 hemoliz edilm\u0259d\u0259n d\u0259rhal ay\u00adr\u0131l\u00admal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259\u00adrilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Lateks aqql\u00fctinasiya<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan qan\/antikoaqulyant nisb\u0259ti, laxtal\u0131, hemolizli. heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:<\/strong>\u00a050-150%<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u0130nsanlarda \u0259n \u00e7ox rast\u00adlanan anadan g\u0259lm\u0259 qanaxma poz\u00ad\u011funlu\u011fu olan von Willebrand x\u0259s\u00adt\u0259liyinin t\u0259yinind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

VON WILLERBAND FAKTOR ANT\u0130GEN\u0130<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Faktor VIII il\u0259 \u0259laq\u0259di antigen<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u011fun olmayan qan\/antikoaqulyant nisb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:<\/strong>\u00a060-150%<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Qazan\u0131lm\u0131\u015f v\u0259 ya kon\u00adgenital von Willerbrand x\u0259st\u0259liyinin (vWD) t\u0259yini, hemofiliya A il\u0259 differensasiyas\u0131nda v\u0259 vWD-li x\u0259st\u0259\u00adl\u0259r\u0259 t\u0259tbiq olunan m\u00fcalic\u0259nin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

WBC (LEYKOS\u0130T)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0A\u011f qan h\u00fcceyr\u0259l\u0259rinin say\u0131; WBC<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>1mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0H\u00fcceyr\u0259 say\u0131m\u0131<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n
Yenido\u011fulmu\u015f<\/td>\n9.0-30.0 K\/mm3<\/sup><\/td>\n<\/tr>\n
<1 ay<\/td>\n9.4-34.0 K\/mm3<\/sup><\/td>\n<\/tr>\n
2-12 ay<\/td>\n5.0-19.5 K\/mm3<\/sup><\/td>\n<\/tr>\n
1-3 ya\u015f<\/td>\n6.0-17.5 K\/mm3<\/sup><\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n5.5-15.5 K\/mm3<\/sup><\/td>\n<\/tr>\n
6-15 ya\u015f<\/td>\n4.5-13.5 K\/mm3<\/sup><\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n4.5-11.0 K\/mm3<\/sup><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Qandak\u0131 a\u011f qan h\u00fcceyr\u0259\u00adl\u0259rinin say\u0131n\u0131n qiym\u0259tl\u0259n\u00addiril\u00adm\u0259\u00adsin\u00add\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

WESTERGREN \u00c7\u00d6KM\u018f S\u00dcR\u018fT\u0130 (ER\u0130TROS\u0130TL\u018fR\u0130N \u00c7\u00d6KM\u018f S\u00dcR\u018fT\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Sedimentasiya; Western \u00e7\u00f6km\u0259 s\u00fcr\u0259ti; ESR, E\u00c7S<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Qara qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01.5 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Qapal\u0131 sistem<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0N\u00fc\u00admu\u00adn\u0259nin laxtal\u0131, hemolizli v\u0259 ya h\u0259d\u00addind\u0259n art\u0131q lipemiyal\u0131 olmas\u0131, uzun m\u00fcdd\u0259t g\u00f6zl\u0259m\u0259si, qan\/sitrat nisb\u0259\u00adtinin d\u00fczg\u00fcn olmamas\u0131 v\u0259 miqda\u00adr\u0131\u00adn\u0131n laz\u0131m olandan az v\u0259 ya \u00e7ox olmas\u0131<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n
Ya\u015f<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
<7g\u00fcn<\/td>\n<10mm\/saat<\/td>\n<10mm\/saat<\/td>\n<\/tr>\n
7g\u00fcn-50ya\u015f<\/td>\n<15mm\/saat<\/td>\n<20mm\/saat<\/td>\n<\/tr>\n
>50ya\u015f<\/td>\n<20mm\/saat<\/td>\n<25mm\/saat<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u0130ltihabi x\u0259st\u0259likl\u0259r, k\u0259skin v\u0259 xroniki infksiyalar, tox<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section><\/div>[\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"

[vc_row][vc_column][\/vc_column][\/vc_row]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-15877","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/pages\/15877","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/comments?post=15877"}],"version-history":[{"count":2,"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/pages\/15877\/revisions"}],"predecessor-version":[{"id":15916,"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/pages\/15877\/revisions\/15916"}],"wp:attachment":[{"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/media?parent=15877"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}